|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases expression multiple interactions |
ISO EXP |
Cycloheximide results in increased expression of ABCB1 mRNA Cycloheximide inhibits the reaction [[Particulate Matter results in increased expression of and results in increased activity of ABCB1 protein] which results in increased uptake of (N-5-(4-nitrobenzofurazan-7-yl)lysyl(8))cyclosporine]; Cycloheximide inhibits the reaction [[Vehicle Emissions results in increased expression of and results in increased activity of ABCB1 protein] which results in increased uptake of (N-5-(4-nitrobenzofurazan-7-yl)lysyl(8))cyclosporine]; Cycloheximide inhibits the reaction [Particulate Matter results in increased expression of and results in increased activity of ABCB1 protein]; Cycloheximide inhibits the reaction [tetrabromobisphenol A results in increased expression of and results in increased activity of ABCB1A protein]; Cycloheximide inhibits the reaction [Vehicle Emissions results in increased expression of and results in increased activity of ABCB1 protein] Cycloheximide promotes the reaction [Reserpine results in increased expression of ABCB1 mRNA] |
CTD |
PMID:7476894 PMID:18474546 PMID:30830211 |
|
NCBI chr 4:22,339,829...22,517,642
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Abcb4 |
ATP binding cassette subfamily B member 4 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetradecanoylphorbol Acetate results in decreased expression of ABCB4 mRNA] |
CTD |
PMID:11331069 |
|
NCBI chr 4:22,133,984...22,192,687
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
multiple interactions increases expression |
ISO |
[Cycloheximide co-treated with Estradiol] results in increased expression of ABCC3 mRNA Cycloheximide results in increased expression of ABCC3 mRNA |
CTD |
PMID:15072547 |
|
NCBI chr10:82,047,308...82,116,928
Ensembl chr10:82,047,863...82,117,109
|
|
G |
Abcc5 |
ATP binding cassette subfamily C member 5 |
multiple interactions decreases expression |
ISO |
[Cycloheximide co-treated with Estradiol] results in decreased expression of ABCC5 mRNA Cycloheximide results in decreased expression of ABCC5 mRNA |
CTD |
PMID:15072547 |
|
NCBI chr11:84,395,982...84,490,215
Ensembl chr11:84,396,033...84,490,211
|
|
G |
Acsl3 |
acyl-CoA synthetase long-chain family member 3 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] affects the expression of ACSL3 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 9:84,569,601...84,593,565
Ensembl chr 9:84,569,597...84,593,565
|
|
G |
Acsl6 |
acyl-CoA synthetase long-chain family member 6 |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [4-(3-(2-propyl-3-hydroxy-4-acetyl)phenoxy)propyloxyphenoxy acetic acid results in increased expression of ACSL6 mRNA] |
CTD |
PMID:10585473 |
|
NCBI chr10:39,654,771...39,717,592
Ensembl chr10:39,655,455...39,719,312
|
|
G |
Adam9 |
ADAM metallopeptidase domain 9 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Hydrogen Peroxide results in increased expression of ADAM9 protein] |
CTD |
PMID:17018608 |
|
NCBI chr16:71,810,377...71,887,926
Ensembl chr16:71,810,377...71,887,926
|
|
G |
Adm |
adrenomedullin |
multiple interactions increases expression |
ISO |
Cycloheximide promotes the reaction [Oxygen deficiency results in increased expression of ADM mRNA] Cycloheximide results in increased expression of ADM mRNA |
CTD |
PMID:11032871 |
|
NCBI chr 1:175,443,189...175,447,260
Ensembl chr 1:175,445,088...175,447,259
|
|
G |
Adora2b |
adenosine A2B receptor |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of ADORA2B mRNA |
CTD |
PMID:19684285 |
|
NCBI chr10:48,569,563...48,586,366
Ensembl chr10:48,569,555...48,586,365
|
|
G |
Adrb2 |
adrenoceptor beta 2 |
increases expression multiple interactions |
ISO |
Cycloheximide results in increased expression of ADRB2 mRNA; Cycloheximide results in increased expression of ADRB2 protein [Cycloheximide co-treated with EDN1 protein] results in increased expression of ADRB2 mRNA; Cycloheximide inhibits the reaction [olodaterol affects the expression of ADRB2 mRNA]; Dactinomycin inhibits the reaction [Cycloheximide results in increased expression of ADRB2 protein]; Formoterol Fumarate promotes the reaction [Cycloheximide results in increased expression of ADRB2 mRNA]; N(6)-benzoyl-cyclic AMP promotes the reaction [Cycloheximide results in increased expression of ADRB2 mRNA] |
CTD |
PMID:22483689 PMID:24705868 |
|
NCBI chr18:57,513,792...57,515,834
Ensembl chr18:57,513,793...57,515,834
|
|
G |
Ago3 |
argonaute RISC catalytic component 3 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Thapsigargin affects the localization of AGO3 mRNA] |
CTD |
PMID:29576526 |
|
NCBI chr 5:144,355,792...144,436,509
Ensembl chr 5:144,364,269...144,436,509
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions increases localization decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide results in decreased expression of AHR protein]; Cycloheximide inhibits the reaction [TGFB1 protein results in decreased expression of AHR mRNA]; Cycloheximide promotes the reaction [Tetrachlorodibenzodioxin results in increased degradation of and results in decreased expression of AHR protein] [Cycloheximide results in increased activity of [AHR protein binds to ARNT protein]] which results in increased expression of CYP1A1 mRNA; [Tretinoin co-treated with Cycloheximide] results in increased expression of AHR mRNA; AHR protein promotes the reaction [Cycloheximide results in increased expression of TIPARP mRNA]; Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased degradation of AHR protein]; Cycloheximide promotes the reaction [Methylcholanthrene promotes the reaction [AHR protein binds to CYP1A1 enhancer]]; Cycloheximide promotes the reaction [Tetrachlorodibenzodioxin affects the localization of AHR protein]; Cycloheximide results in increased activity of [AHR protein binds to ARNT protein] Cycloheximide results in increased localization of AHR protein |
CTD |
PMID:9145908 PMID:10777561 PMID:12002481 PMID:12147270 PMID:15385644 PMID:16226227 PMID:20570689 PMID:21807577 |
|
NCBI chr 6:54,963,990...55,001,806
Ensembl chr 6:54,963,990...55,001,464
|
|
G |
Akap5 |
A-kinase anchoring protein 5 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of AKAP5 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 6:99,356,509...99,361,909
Ensembl chr 6:99,356,509...99,361,909
|
|
G |
Akap6 |
A-kinase anchoring protein 6 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of AKAP6 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 6:73,553,111...73,991,992
Ensembl chr 6:73,553,210...73,990,534
|
|
G |
Akr1c3 |
aldo-keto reductase family 1, member C3 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [cadmium acetate results in increased expression of AKR1C3 protein] |
CTD |
PMID:21787718 |
|
NCBI chr17:69,761,126...69,778,021
Ensembl chr17:69,761,118...69,778,021
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions increases phosphorylation |
EXP ISO |
Cycloheximide inhibits the reaction [[Hydrogen Peroxide co-treated with sodium arsenite] results in increased phosphorylation of AKT1 protein] Cycloheximide results in increased phosphorylation of AKT1 protein |
CTD |
PMID:12472888 PMID:28634229 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
Aldh1a3 |
aldehyde dehydrogenase 1 family, member A3 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of ALDH1A3 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 1:127,302,920...127,337,828
Ensembl chr 1:127,301,128...127,337,882
|
|
G |
Aldh3a1 |
aldehyde dehydrogenase 3 family, member A1 |
multiple interactions |
EXP |
Cycloheximide promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of ALDH3A1 mRNA] |
CTD |
PMID:1953764 |
|
NCBI chr10:47,490,168...47,499,855
Ensembl chr10:47,490,153...47,499,876
|
|
G |
Aldh3a2 |
aldehyde dehydrogenase 3 family, member A2 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of ALDH3A2 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr10:47,525,486...47,546,535
Ensembl chr10:47,525,493...47,546,345
|
|
G |
Alox5ap |
arachidonate 5-lipoxygenase activating protein |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of ALOX5AP mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr12:6,854,930...6,879,112
Ensembl chr12:6,854,920...6,879,154
|
|
G |
Alpi |
alkaline phosphatase, intestinal |
decreases activity multiple interactions |
ISO EXP |
Cycloheximide results in decreased activity of ALPI protein Cycloheximide inhibits the reaction [Fish Oils results in increased activity of ALPI protein] |
CTD |
PMID:15599000 PMID:20362602 |
|
NCBI chr 9:94,197,616...94,201,910
Ensembl chr 9:94,197,618...94,201,084
|
|
G |
Amhr2 |
anti-Mullerian hormone receptor type 2 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of AMHR2 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 7:144,052,202...144,060,678
Ensembl chr 7:144,052,061...144,060,685
|
|
G |
Ank2 |
ankyrin 2 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of ANK2 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 2:231,224,643...231,522,655
Ensembl chr 2:231,226,949...231,648,122
|
|
G |
Ankrd27 |
ankyrin repeat domain 27 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of ANKRD27 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 1:91,857,048...91,958,763
Ensembl chr 1:91,857,057...91,958,763
|
|
G |
Aoc1 |
amine oxidase, copper containing 1 |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [Epinephrine results in increased activity of AOC1 protein]; Cycloheximide inhibits the reaction [Isoproterenol results in increased activity of AOC1 protein]; Cycloheximide inhibits the reaction [Terbutaline results in increased activity of AOC1 protein] |
CTD |
PMID:2860926 PMID:6218830 |
|
NCBI chr 4:78,496,043...78,515,582
Ensembl chr 4:78,496,043...78,515,584
|
|
G |
Apaf1 |
apoptotic peptidase activating factor 1 |
decreases expression multiple interactions |
ISO |
Cycloheximide results in decreased expression of APAF1 mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in decreased expression of APAF1 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 7:31,699,309...31,784,192
Ensembl chr 7:31,699,885...31,784,192
|
|
G |
Aqp1 |
aquaporin 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [cobaltous chloride results in increased expression of AQP1 mRNA] |
CTD |
PMID:22415096 |
|
NCBI chr 4:85,551,503...85,563,683
Ensembl chr 4:85,551,502...85,569,360
|
|
G |
Aqp4 |
aquaporin 4 |
multiple interactions |
EXP |
[Lactic Acid co-treated with Cycloheximide] results in increased expression of AQP4 protein |
CTD |
PMID:18406487 |
|
NCBI chr18:6,766,009...6,782,757
Ensembl chr18:6,765,945...6,782,996
|
|
G |
Areg |
amphiregulin |
multiple interactions increases expression |
ISO |
[Cycloheximide co-treated with Estradiol] results in increased expression of AREG mRNA Cycloheximide results in increased expression of AREG mRNA |
CTD |
PMID:15072547 PMID:15228094 |
|
NCBI chr14:18,521,921...18,531,179
Ensembl chr14:18,521,930...18,531,179
|
|
G |
Armc5 |
armadillo repeat containing 5 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of ARMC5 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 1:199,655,069...199,662,419
Ensembl chr 1:199,655,660...199,662,427
|
|
G |
Arnt |
aryl hydrocarbon receptor nuclear translocator |
multiple interactions |
ISO |
[Cycloheximide results in increased activity of [AHR protein binds to ARNT protein]] which results in increased expression of CYP1A1 mRNA; Cycloheximide promotes the reaction [Methylcholanthrene promotes the reaction [ARNT protein binds to CYP1A1 enhancer]]; Cycloheximide results in increased activity of [AHR protein binds to ARNT protein] |
CTD |
PMID:12002481 PMID:20570689 |
|
NCBI chr 2:196,594,178...196,651,486
Ensembl chr 2:196,594,303...196,651,179
|
|
G |
Asb1 |
ankyrin repeat and SOCS box-containing 1 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of ASB1 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 9:98,668,231...98,689,471
Ensembl chr 9:98,668,231...98,684,900
|
|
G |
Atf3 |
activating transcription factor 3 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of ATF3 protein] |
CTD |
PMID:23593480 |
|
NCBI chr13:109,817,892...109,849,632
Ensembl chr13:109,817,728...109,849,632
|
|
G |
Atf4 |
activating transcription factor 4 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Cadmium Chloride results in increased expression of ATF4]]; Cycloheximide inhibits the reaction [Capsaicin results in increased expression of ATF4 protein] Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of ATF4 protein] |
CTD |
PMID:18533110 PMID:23593480 PMID:24057571 |
|
NCBI chr 7:121,480,723...121,482,781
Ensembl chr 7:121,480,723...121,482,772
|
|
G |
Atg13 |
autophagy related 13 |
decreases expression |
ISO |
Cycloheximide results in decreased expression of ATG13 protein |
CTD |
PMID:27629431 |
|
NCBI chr 3:80,580,549...80,614,554
Ensembl chr 3:80,581,247...80,601,410
|
|
G |
Atp7a |
ATPase copper transporting alpha |
multiple interactions decreases expression |
EXP |
cupric chloride inhibits the reaction [Cycloheximide results in decreased expression of ATP7A protein] |
CTD |
PMID:23174565 |
|
NCBI chr X:77,076,085...77,193,644
Ensembl chr X:77,076,106...77,193,644
|
|
G |
Avpr1a |
arginine vasopressin receptor 1A |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of AVPR1A mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 7:67,341,366...67,345,290
Ensembl chr 7:67,341,080...67,345,308
|
|
G |
Bach1 |
BTB domain and CNC homolog 1 |
decreases expression multiple interactions |
ISO |
Cycloheximide results in decreased expression of BACH1 protein tetrachlorobenzoquinone promotes the reaction [Cycloheximide results in decreased expression of BACH1 protein] |
CTD |
PMID:27393035 |
|
NCBI chr11:27,364,913...27,398,713
Ensembl chr11:27,364,916...27,398,842
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [TGFB1 protein results in increased expression of BAX protein] |
CTD |
PMID:9790906 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bbox1 |
gamma-butyrobetaine hydroxylase 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of BBOX1 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 3:101,425,684...101,474,848
Ensembl chr 3:101,427,055...101,474,890
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO |
BCL2 protein inhibits the reaction [[Cycloheximide co-treated with TNFSF10 protein] results in increased activity of CASP3 protein]; Cycloheximide inhibits the reaction [Paclitaxel results in increased phosphorylation of BCL2 protein] |
CTD |
PMID:11726273 PMID:22343715 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
increases expression multiple interactions |
ISO |
Cycloheximide results in increased expression of BCL2L1 protein alternative form Dexamethasone inhibits the reaction [Cycloheximide results in increased expression of BCL2L1 protein] |
CTD |
PMID:9326359 |
|
NCBI chr 3:148,259,594...148,314,191
Ensembl chr 3:148,259,596...148,313,810
|
|
G |
Bcl2l14 |
BCL2 like 14 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of BCL2L14 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 4:168,139,964...168,183,726
Ensembl chr 4:168,142,271...168,183,096
|
|
G |
Bdh1 |
3-hydroxybutyrate dehydrogenase 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of BDH1 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr11:72,577,547...72,619,435
Ensembl chr11:72,578,533...72,614,176
|
|
G |
Becn1 |
beclin 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [arsenic trioxide results in increased expression of BECN1 protein] |
CTD |
PMID:16882451 |
|
NCBI chr10:89,209,944...89,225,297
Ensembl chr10:89,209,940...89,225,297
|
|
G |
Bglap |
bone gamma-carboxyglutamate protein |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [[Genistein co-treated with Zinc Sulfate] results in increased expression of BGLAP mRNA]; Cycloheximide inhibits the reaction [[Genistein co-treated with Zinc] results in increased expression of BGLAP mRNA] |
CTD |
PMID:17203194 |
|
NCBI chr 2:187,741,770...187,748,445
Ensembl chr 2:187,741,770...187,742,747
|
|
G |
Bid |
BH3 interacting domain death agonist |
multiple interactions |
ISO |
[Cycloheximide co-treated with TNF] results in increased cleavage of BID protein; Cycloheximide inhibits the reaction [vorinostat results in increased cleavage of BID protein]; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of BID protein]; ITPK1 mutant form promotes the reaction [[Cycloheximide co-treated with TNF protein] results in increased cleavage of BID protein] |
CTD |
PMID:11535817 PMID:12925536 |
|
NCBI chr 4:153,439,812...153,465,247
Ensembl chr 4:153,442,218...153,465,203
|
|
G |
Bnip3 |
BCL2 interacting protein 3 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [manganese chloride results in increased expression of BNIP3 protein] |
CTD |
PMID:19442826 |
|
NCBI chr 1:211,248,098...211,265,282
Ensembl chr 1:211,248,098...211,265,282
|
|
G |
Brca1 |
BRCA1, DNA repair associated |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Nitrogen Mustard Compounds results in decreased expression of BRCA1 mRNA] Cycloheximide inhibits the reaction [Thapsigargin affects the localization of BRCA1 mRNA] |
CTD |
PMID:10344722 PMID:29576526 |
|
NCBI chr10:89,394,821...89,455,093
Ensembl chr10:89,394,803...89,454,681
|
|
G |
Brca2 |
BRCA2, DNA repair associated |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Nitrogen Mustard Compounds results in decreased expression of BRCA2 mRNA] |
CTD |
PMID:10344722 |
|
NCBI chr12:503,660...544,754
Ensembl chr12:504,007...544,748
|
|
G |
Calb1 |
calbindin 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of CALB1 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 5:29,538,380...29,562,774
Ensembl chr 5:29,538,380...29,562,773
|
|
G |
Camlg |
calcium modulating ligand |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CAMLG mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr17:9,523,792...9,534,683
Ensembl chr17:9,523,795...9,534,653
|
|
G |
Casp1 |
caspase 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [tetrachlorobenzoquinone results in increased expression of CASP1 protein]; Cycloheximide inhibits the reaction [tetrachlorobenzoquinone results in increased secretion of CASP1 protein modified form]; Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CASP1 mRNA] |
CTD |
PMID:11007951 PMID:26901245 |
|
NCBI chr 8:2,605,743...2,614,637
Ensembl chr 8:2,604,962...2,614,631
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity |
ISO EXP |
[Cycloheximide co-treated with TNF] results in increased cleavage of and results in increased activity of CASP3 protein; [Cycloheximide co-treated with TNFSF10 protein] results in increased activity of CASP3 protein; BCL2 protein inhibits the reaction [[Cycloheximide co-treated with TNFSF10 protein] results in increased activity of CASP3 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[Cycloheximide co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP3 protein]; Cycloheximide promotes the reaction [FAS protein results in increased activity of CASP3 protein]; IFI6 protein inhibits the reaction [Cycloheximide results in increased activity of CASP3 protein]; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of and results in increased activity of CASP3 protein] Cycloheximide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein co-treated with Cryptoxanthins] promotes the reaction [Zinc Sulfate results in increased expression of CASP3 mRNA]]; Cycloheximide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein co-treated with Zinc Sulfate] promotes the reaction [Cryptoxanthins results in increased expression of CASP3 mRNA]]; Cycloheximide inhibits the reaction [aluminum maltolate results in increased activity of CASP3 protein]; Cycloheximide inhibits the reaction [Cryptoxanthins promotes the reaction [Zinc Sulfate results in increased expression of CASP3 mRNA]]; Cycloheximide inhibits the reaction [Genistein promotes the reaction [[Zinc Sulfate co-treated with CSF1 protein co-treated with TNFSF11 protein] results in increased expression of CASP3 mRNA]]; Cycloheximide inhibits the reaction [Genistein promotes the reaction [Zinc Sulfate results in increased expression of CASP3 mRNA]]; Cycloheximide inhibits the reaction [Zinc Sulfate promotes the reaction [Cryptoxanthins results in increased expression of CASP3 mRNA]] obeticholic acid promotes the reaction [Cycloheximide results in increased activity of CASP3 protein] |
CTD |
PMID:12760867 PMID:12925536 PMID:14502240 PMID:15537749 PMID:15685448 PMID:15860571 PMID:17295206 PMID:18222423 PMID:18636177 PMID:22343715 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp4 |
caspase 4 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CASP4 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 8:2,616,391...2,651,682
Ensembl chr 8:2,635,851...2,651,652
|
|
G |
Casp7 |
caspase 7 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tretinoin results in increased expression of CASP7 mRNA]; Cycloheximide promotes the reaction [FAS protein results in increased activity of CASP7 protein] |
CTD |
PMID:12760867 PMID:16166294 |
|
NCBI chr 1:277,190,557...277,242,779
Ensembl chr 1:277,190,964...277,242,774
|
|
G |
Casp8 |
caspase 8 |
multiple interactions increases activity |
ISO |
[Cycloheximide co-treated with TNF] results in increased cleavage of and results in increased activity of CASP8 protein; [Cycloheximide co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP8 protein; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[Cycloheximide co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP8 protein]; Cycloheximide promotes the reaction [FAS protein results in increased activity of CASP8 protein]; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of and results in increased activity of CASP8 protein] Cycloheximide results in increased activity of CASP8 protein |
CTD |
PMID:12760867 PMID:12925536 PMID:15924153 PMID:18222423 |
|
NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
|
|
G |
Casp9 |
caspase 9 |
multiple interactions increases activity |
ISO |
[Cycloheximide co-treated with TNF] results in increased activity of CASP9 protein; [Cycloheximide co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP9 protein; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased activity of CASP9 protein] Cycloheximide results in increased activity of CASP9 protein |
CTD |
PMID:12925536 PMID:14502240 PMID:18222423 |
|
NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [Clofibrate results in increased expression of CAT protein]; Cycloheximide inhibits the reaction [mono-(2-ethylhexyl)phthalate results in increased expression of CAT protein] |
CTD |
PMID:6845354 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Catsper4 |
cation channel, sperm associated 4 |
affects response to substance |
ISO |
CATSPER4 gene SNP affects the susceptibility to Cycloheximide |
CTD |
PMID:25622337 |
|
NCBI chr 5:152,430,052...152,446,808
Ensembl chr 5:152,430,025...152,446,775
|
|
G |
Cav1 |
caveolin 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of CAV1 mRNA] |
CTD |
PMID:15314095 |
|
NCBI chr 4:44,597,123...44,630,206
Ensembl chr 4:44,597,123...44,630,200
|
|
G |
Cbx1 |
chromobox 1 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of CBX1 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr10:84,656,698...84,677,112
Ensembl chr10:84,669,914...84,675,741
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions increases expression |
ISO |
Cycloheximide inhibits the reaction [TNF protein results in increased expression of CCL2 protein]; Cycloheximide inhibits the reaction [tofacitinib inhibits the reaction [TNF protein results in increased expression of CCL2 protein]]; TNF protein promotes the reaction [Cycloheximide results in increased expression of CCL2 mRNA]; Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of CCL2 mRNA]] |
CTD |
PMID:21146893 PMID:22121136 |
|
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
increases expression multiple interactions |
ISO |
Cycloheximide results in increased expression of CCL5 mRNA Cycloheximide inhibits the reaction [TNF protein results in increased expression of CCL5 protein]; Cycloheximide inhibits the reaction [tofacitinib inhibits the reaction [TNF protein results in increased expression of CCL5 protein]]; TNF protein promotes the reaction [Cycloheximide results in increased expression of CCL5 mRNA]; Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of CCL5 mRNA]] |
CTD |
PMID:21146893 PMID:22121136 |
|
NCBI chr10:70,739,764...70,744,303
Ensembl chr10:70,739,800...70,744,315
|
|
G |
Ccn1 |
cellular communication network factor 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Acetylcysteine results in increased expression of CCN1 protein] |
CTD |
PMID:21055460 |
|
NCBI chr 2:251,529,354...251,532,312
Ensembl chr 2:251,529,354...251,532,312
|
|
G |
Ccn2 |
cellular communication network factor 2 |
increases expression multiple interactions |
ISO |
Cycloheximide results in increased expression of CCN2 mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in decreased expression of CCN2 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 1:21,851,657...21,854,773
Ensembl chr 1:21,851,660...21,854,773
|
|
G |
Ccn3 |
cellular communication network factor 3 |
multiple interactions increases expression |
ISO |
[Cycloheximide co-treated with Estradiol] results in decreased expression of CCN3 mRNA Cycloheximide results in increased expression of CCN3 mRNA |
CTD |
PMID:15072547 |
|
NCBI chr 7:94,375,134...94,382,154
Ensembl chr 7:94,375,020...94,383,024
|
|
G |
Ccn4 |
cellular communication network factor 4 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [2,2'-(hydroxynitrosohydrazono)bis-ethanamine results in increased expression of CCN4 mRNA] |
CTD |
PMID:19238344 |
|
NCBI chr 7:107,695,227...107,723,759
Ensembl chr 7:107,695,215...107,723,772
|
|
G |
Ccna2 |
cyclin A2 |
multiple interactions decreases expression |
ISO |
[Cycloheximide co-treated with Estradiol] results in increased expression of CCNA2 mRNA Cycloheximide results in decreased expression of CCNA2 mRNA |
CTD |
PMID:15072547 |
|
NCBI chr 2:123,274,727...123,282,266
Ensembl chr 2:123,275,881...123,282,214
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions |
ISO |
[gingerol co-treated with Cycloheximide] results in increased degradation of CCND1 protein; Cycloheximide inhibits the reaction [CXCL8 protein results in increased expression of CCND1 protein]; Cycloheximide inhibits the reaction [EIF4E protein modified form inhibits the reaction [sodium arsenite results in decreased expression of CCND1 protein]] |
CTD |
PMID:17606477 PMID:18058799 PMID:25923732 |
|
NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
|
|
G |
Ccnd3 |
cyclin D3 |
affects expression multiple interactions |
ISO |
Cycloheximide affects the expression of CCND3 mRNA Cycloheximide affects the reaction [Estradiol affects the expression of CCND3 mRNA] |
CTD |
PMID:9094091 |
|
NCBI chr 9:15,404,816...15,410,905
Ensembl chr 9:15,404,822...15,410,943
|
|
G |
Cct5 |
chaperonin containing TCP1 subunit 5 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in decreased expression of CCT5 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 2:84,667,578...84,678,730
Ensembl chr 2:84,667,633...84,678,790
|
|
G |
Cd38 |
CD38 molecule |
multiple interactions |
ISO |
Cycloheximide affects the reaction [Tretinoin results in increased expression of CD38 mRNA] |
CTD |
PMID:21393419 |
|
NCBI chr14:71,714,768...71,754,990
Ensembl chr14:71,715,269...71,754,672
|
|
G |
Cd3e |
CD3e molecule |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of CD3E mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 8:49,297,604...49,309,370
Ensembl chr 8:49,297,608...49,308,806
|
|
G |
Cd44 |
CD44 molecule (Indian blood group) |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of and results in increased activity of CD44 protein] |
CTD |
PMID:9929743 |
|
NCBI chr 3:92,695,083...92,783,820
Ensembl chr 3:92,696,313...92,783,658
|
|
G |
Cd47 |
Cd47 molecule |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of CD47 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr11:53,511,485...53,575,754
Ensembl chr11:53,514,595...53,575,175
|
|
G |
Cd63 |
Cd63 molecule |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CD63 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 7:3,320,250...3,335,583
Ensembl chr 7:3,320,103...3,335,582
|
|
G |
Cd8a |
CD8a molecule |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of CD8A mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 4:99,217,640...99,243,352
Ensembl chr 4:99,239,115...99,243,351
|
|
G |
Cdc42se2 |
CDC42 small effector 2 |
increases expression multiple interactions |
ISO |
Cycloheximide results in increased expression of CDC42SE2 mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] affects the expression of CDC42SE2 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr10:40,054,393...40,122,915
Ensembl chr10:40,054,400...40,122,915
|
|
G |
Cdca5 |
cell division cycle associated 5 |
increases expression multiple interactions |
ISO |
Cycloheximide results in increased expression of CDCA5 mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of CDCA5 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 1:221,448,661...221,462,235
Ensembl chr 1:221,448,661...221,462,233
|
|
G |
Cdca7l |
cell division cycle associated 7 like |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [MLN7243 results in increased sumoylation of CDCA7L protein] |
CTD |
PMID:31285264 |
|
NCBI chr 6:145,739,570...145,785,607
Ensembl chr 6:145,740,035...145,785,606
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Dexamethasone results in decreased expression of CDK2 mRNA] |
CTD |
PMID:12800980 |
|
NCBI chr 7:3,124,953...3,132,533
Ensembl chr 7:3,124,954...3,132,457
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions decreases expression |
ISO EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Cycloheximide results in decreased expression of CDKN1A protein]; Cycloheximide inhibits the reaction [Resveratrol results in increased expression of CDKN1A mRNA]; Cycloheximide inhibits the reaction [Troglitazone results in increased expression of CDKN1A protein]; Furazolidone promotes the reaction [Cycloheximide results in decreased expression of CDKN1A protein]; IGF1 protein inhibits the reaction [Cycloheximide results in decreased expression of CDKN1A protein]; PSME3 protein affects the reaction [Cycloheximide results in decreased expression of CDKN1A protein] Cycloheximide promotes the reaction [Dexamethasone results in decreased expression of CDKN1A protein]; Cycloheximide promotes the reaction [Semaxinib results in increased expression of CDKN1A mRNA] Cycloheximide inhibits the reaction [manganese chloride results in increased expression of CDKN1A protein] Cycloheximide results in decreased expression of CDKN1A mRNA; Cycloheximide results in decreased expression of CDKN1A protein |
CTD |
PMID:10441511 PMID:12690110 PMID:22542671 PMID:24211769 PMID:26687534 PMID:28424418 PMID:28940008 PMID:31645432 |
|
NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
|
|
G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
increases expression |
ISO |
Cycloheximide results in increased expression of CDKN2A mRNA |
CTD |
PMID:17257637 |
|
NCBI chr 5:107,823,323...107,832,405
Ensembl chr 5:107,823,330...107,841,175
|
|
G |
Cflar |
CASP8 and FADD-like apoptosis regulator |
decreases expression multiple interactions |
ISO |
Cycloheximide results in decreased expression of CFLAR protein; Cycloheximide results in decreased expression of CFLAR protein alternative form; Cycloheximide results in decreased expression of CFLAR protein modified form shogaol promotes the reaction [Cycloheximide results in decreased expression of CFLAR protein modified form] |
CTD |
PMID:12663669 PMID:15924153 PMID:16077199 PMID:16951203 PMID:25619640 |
|
NCBI chr 9:65,534,608...65,586,395
Ensembl chr 9:65,534,704...65,587,251
|
|
G |
Cftr |
CF transmembrane conductance regulator |
affects expression |
EXP |
Cycloheximide affects the expression of CFTR mRNA |
CTD |
PMID:17290305 |
|
NCBI chr 4:42,693,263...42,860,679
Ensembl chr 4:42,692,836...42,860,676
|
|
G |
Chrm1 |
cholinergic receptor, muscarinic 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Dihydrotestosterone results in decreased expression of CHRM1 mRNA] |
CTD |
PMID:17624924 |
|
NCBI chr 1:224,869,087...224,885,101
Ensembl chr 1:224,882,439...224,884,205
|
|
G |
Cish |
cytokine inducible SH2-containing protein |
increases expression |
ISO |
Cycloheximide results in increased expression of CISH mRNA |
CTD |
PMID:23237828 |
|
NCBI chr 8:116,054,547...116,059,494
Ensembl chr 8:116,054,465...116,060,723
|
|
G |
Cited2 |
Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] affects the expression of CITED2 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 1:12,823,363...12,825,806
Ensembl chr 1:12,823,363...12,825,786
|
|
G |
Ckb |
creatine kinase B |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [Estradiol results in increased expression of CKB protein]; Cycloheximide inhibits the reaction [Methoxychlor results in increased expression of CKB protein] |
CTD |
PMID:7839363 |
|
NCBI chr 6:136,142,956...136,145,838
Ensembl chr 6:136,142,956...136,145,837
|
|
G |
Clcn3 |
chloride voltage-gated channel 3 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of CLCN3 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr16:32,448,821...32,520,649
Ensembl chr16:32,449,116...32,519,148
|
|
G |
Cnr1 |
cannabinoid receptor 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Dronabinol results in increased expression of CNR1 mRNA]; Cycloheximide inhibits the reaction [Morphine inhibits the reaction [TNF protein results in increased expression of CNR1 mRNA]] Cycloheximide results in decreased expression of and affects the localization of CNR1 protein |
CTD |
PMID:17041005 PMID:22258905 PMID:27513693 |
|
NCBI chr 5:49,307,584...49,333,064
Ensembl chr 5:49,311,030...49,333,056
|
|
G |
Col10a1 |
collagen type X alpha 1 chain |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tretinoin results in increased expression of COL10A1 mRNA] |
CTD |
PMID:16350840 |
|
NCBI chr20:41,180,295...41,190,664
Ensembl chr20:41,184,287...41,189,633
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [[Genistein co-treated with Zinc Sulfate] results in increased expression of COL1A1 mRNA]; Cycloheximide inhibits the reaction [[Genistein co-treated with Zinc] results in increased expression of COL1A1 mRNA]; Cycloheximide inhibits the reaction [Cryptoxanthins results in increased expression of COL1A1 mRNA] |
CTD |
PMID:15962303 PMID:17203194 |
|
NCBI chr10:82,745,801...82,762,790
Ensembl chr10:82,745,801...82,762,789
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Thapsigargin affects the localization of CREB1 mRNA] |
CTD |
PMID:29576526 |
|
NCBI chr 9:71,229,753...71,298,994
Ensembl chr 9:71,230,108...71,293,435
|
|
G |
Crppa |
CDP-L-ribitol pyrophosphorylase A |
affects response to substance |
ISO |
CRPPA gene SNP affects the susceptibility to Cycloheximide |
CTD |
PMID:25622337 |
|
NCBI chr 6:55,880,136...56,159,466
Ensembl chr 6:55,881,387...56,159,464
|
|
G |
Cryl1 |
crystallin, lambda 1 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of CRYL1 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr15:37,543,727...37,663,586
Ensembl chr15:37,543,727...37,663,584
|
|
G |
Csf1 |
colony stimulating factor 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein co-treated with Cryptoxanthins] promotes the reaction [Zinc Sulfate results in increased expression of CASP3 mRNA]]; Cycloheximide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein co-treated with Zinc Sulfate] promotes the reaction [Cryptoxanthins results in increased expression of CASP3 mRNA]]; Cycloheximide inhibits the reaction [Genistein promotes the reaction [[Zinc Sulfate co-treated with CSF1 protein co-treated with TNFSF11 protein] results in increased expression of CASP3 mRNA]]; Cycloheximide inhibits the reaction [Zinc results in increased expression of CSF1 mRNA] |
CTD |
PMID:12112025 PMID:17295206 PMID:18636177 |
|
NCBI chr 2:210,522,370...210,550,546
Ensembl chr 2:210,522,375...210,550,560
|
|
G |
Csf2 |
colony stimulating factor 2 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [IL1B results in increased secretion of CSF2 protein]; Cycloheximide inhibits the reaction [Particulate Matter results in increased secretion of CSF2 protein]; Cycloheximide inhibits the reaction [Vehicle Emissions results in increased secretion of CSF2 protein] |
CTD |
PMID:9606035 PMID:10645887 |
|
NCBI chr10:39,602,089...39,604,070
Ensembl chr10:39,602,089...39,604,070
|
|
G |
Csnk1d |
casein kinase 1, delta |
multiple interactions |
ISO |
Cycloheximide promotes the reaction [Tetrachlorodibenzodioxin results in decreased expression of CSNK1D mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr10:110,147,786...110,182,413
Ensembl chr10:110,148,600...110,182,408
|
|
G |
Ctnnb1 |
catenin beta 1 |
decreases expression multiple interactions |
ISO |
Cycloheximide results in decreased expression of CTNNB1 protein Phenobarbital affects the reaction [Cycloheximide results in decreased expression of CTNNB1 protein] |
CTD |
PMID:27693619 |
|
NCBI chr 8:129,601,511...129,628,378
Ensembl chr 8:129,617,812...129,627,372
|
|
G |
Ctsb |
cathepsin B |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [Azithromycin results in increased activity of CTSB protein] |
CTD |
PMID:8830663 |
|
NCBI chr15:46,316,741...46,337,613
Ensembl chr15:46,316,741...46,337,612
|
|
G |
Cul2 |
cullin 2 |
multiple interactions |
ISO |
CUL2 protein affects the reaction [Cycloheximide results in increased degradation of MAF1 protein] |
CTD |
PMID:31645432 |
|
NCBI chr17:56,952,480...56,992,716
Ensembl chr17:56,952,480...56,992,694
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [TNF protein results in increased expression of CXCL10 protein]; Cycloheximide inhibits the reaction [tofacitinib inhibits the reaction [TNF protein results in increased expression of CXCL10 protein]] |
CTD |
PMID:22121136 |
|
NCBI chr14:17,210,733...17,212,930
Ensembl chr14:17,210,733...17,212,930
|
|
G |
Cycs |
cytochrome c, somatic |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of CYCS mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 4:80,331,226...80,333,326
Ensembl chr 4:80,331,227...80,333,326
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
decreases expression |
EXP |
Cycloheximide results in decreased expression of CYP11A1 protein |
CTD |
PMID:21126571 |
|
NCBI chr 8:62,798,317...62,809,848
Ensembl chr 8:62,779,875...62,809,893
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
decreases activity decreases expression |
ISO EXP |
Cycloheximide results in decreased activity of CYP19A1 protein Cycloheximide results in decreased expression of CYP19A1 protein |
CTD |
PMID:16480277 PMID:21126571 |
|
NCBI chr 8:58,744,849...58,772,408
Ensembl chr 8:58,744,849...58,772,408
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
affects expression multiple interactions increases expression |
EXP ISO |
Cycloheximide affects the expression of CYP1A1 mRNA [Cycloheximide results in increased activity of [AHR protein binds to ARNT protein]] which results in increased expression of CYP1A1 mRNA; [Piperonyl Butoxide co-treated with Cycloheximide] results in increased expression of CYP1A1 mRNA; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Cycloheximide results in increased expression of CYP1A1 mRNA]; Cycloheximide affects the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA]; Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; Cycloheximide promotes the reaction [6-(4-diethylamino)phenyl-7-chloro-5,8-quinolinedione results in increased expression of CYP1A1 mRNA]; Cycloheximide promotes the reaction [Cadmium Chloride results in increased expression of CYP1A1 mRNA]; Cycloheximide promotes the reaction [Copper results in increased expression of CYP1A1 mRNA]; Cycloheximide promotes the reaction [Lead results in increased expression of CYP1A1 mRNA]; Cycloheximide promotes the reaction [Mercury results in increased expression of CYP1A1 mRNA]; Cycloheximide promotes the reaction [Methylcholanthrene promotes the reaction [AHR protein binds to CYP1A1 enhancer]]; Cycloheximide promotes the reaction [Methylcholanthrene promotes the reaction [ARNT protein binds to CYP1A1 enhancer]]; Cycloheximide promotes the reaction [Methylcholanthrene results in increased expression of CYP1A1 mRNA]; Cycloheximide promotes the reaction [Semaxinib results in increased expression of CYP1A1 mRNA]; Cycloheximide promotes the reaction [sodium arsenite results in increased expression of CYP1A1 mRNA]; Cycloheximide promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; Dactinomycin promotes the reaction [Cycloheximide results in increased expression of CYP1A1 mRNA] 3'-methoxy-4'-nitroflavone inhibits the reaction [Cycloheximide results in increased expression of CYP1A1 mRNA]; [Cycloheximide co-treated with Harmaline] results in decreased expression of CYP1A1 protein; [Cycloheximide co-treated with harmalol] results in decreased expression of CYP1A1 protein; [Cycloheximide co-treated with Tetrachlorodibenzodioxin] results in increased expression of CYP1A1 mRNA; [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of CYP1A1 mRNA; alpha-naphthoflavone inhibits the reaction [Cycloheximide results in increased expression of CYP1A1 mRNA]; Benzimidazoles promotes the reaction [Cycloheximide results in increased expression of CYP1A1 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Cycloheximide co-treated with Harmaline] results in decreased expression of CYP1A1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Cycloheximide co-treated with harmalol] results in decreased expression of CYP1A1 protein]; beta-Naphthoflavone promotes the reaction [Cycloheximide results in increased expression of CYP1A1 mRNA]; Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; Cycloheximide inhibits the reaction [TGFB1 protein inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]]; Cycloheximide promotes the reaction [[Benzo(a)pyrene co-treated with Calcitriol] results in increased expression of CYP1A1 mRNA]; Cycloheximide promotes the reaction [Skatole results in increased expression of CYP1A1 mRNA]; Cycloheximide promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA] |
CTD |
PMID:1321828 PMID:1849469 PMID:1934297 PMID:2985607 PMID:8647108 PMID:9102211 PMID:9145908 PMID:9233375 PMID:10777561 PMID:11007951 PMID:11516172 PMID:11710520 PMID:12002481 PMID:12111005 PMID:15371557 PMID:15385644 PMID:16093525 PMID:17599377 PMID:17606337 PMID:19244278 PMID:19684285 PMID:20187624 PMID:20570689 PMID:22037238 PMID:28424418 PMID:29524502 |
|
NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
Cycloheximide affects the reaction [Benzo(a)pyrene results in increased expression of CYP1A2 mRNA] |
CTD |
PMID:1849469 |
|
NCBI chr 8:62,451,360...62,458,244
Ensembl chr 8:62,451,329...62,458,301
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
increases expression multiple interactions |
ISO EXP |
Cycloheximide results in increased expression of CYP1B1 mRNA Cycloheximide inhibits the reaction [Vehicle Emissions results in increased expression of CYP1B1 protein] [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of CYP1B1 mRNA; Cycloheximide inhibits the reaction [TGFB1 protein inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1B1 mRNA]] |
CTD |
PMID:9145908 PMID:19684285 PMID:21867498 |
|
NCBI chr 6:2,308,179...2,316,739
Ensembl chr 6:2,307,808...2,316,722
|
|
G |
Cyp24a1 |
cytochrome P450, family 24, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
alpha-naphthoflavone inhibits the reaction [Cycloheximide promotes the reaction [Calcitriol results in increased expression of CYP24A1 mRNA]]; Cycloheximide inhibits the reaction [Calcitriol results in increased expression of CYP24A1 mRNA] |
CTD |
PMID:19244278 |
|
NCBI chr 3:168,097,484...168,111,920
Ensembl chr 3:168,097,485...168,111,920
|
|
G |
Cyp2a3 |
cytochrome P450, family 2, subfamily a, polypeptide 3 |
increases expression |
ISO |
Cycloheximide results in increased expression of CYP2A5 mRNA |
CTD |
PMID:9007836 |
|
NCBI chr 1:83,653,248...83,662,118
Ensembl chr 1:83,653,234...83,766,484
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions increases degradation |
ISO EXP |
(4-amidinophenyl)methanesulfonyl fluoride inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein]; 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein]; acetonitrile inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein]; Biotin inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein]; Carbon Tetrachloride promotes the reaction [Cycloheximide results in increased degradation of CYP2E1 protein]; Cycloheximide inhibits the reaction [CYP2E1 protein results in increased oxidation of 4-nitrophenol]; Cycloheximide inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [CYP2E1 protein results in increased oxidation of 4-nitrophenol]]; Cycloheximide promotes the reaction [Carbon Tetrachloride results in increased degradation of CYP2E1 protein]; Dimethyl Sulfoxide inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein]; Edetic Acid inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein]; Egtazic Acid inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein]; Ethanol inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein]; fomepizole inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein]; Glycerol inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein]; leupeptin inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein]; Tetradecanoylphorbol Acetate inhibits the reaction [Cycloheximide inhibits the reaction [CYP2E1 protein results in increased oxidation of 4-nitrophenol]]; Tosyllysine Chloromethyl Ketone inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein] Cycloheximide inhibits the reaction [pyridine results in increased activity of CYP2E1 protein]; Cycloheximide inhibits the reaction [pyridine results in increased expression of CYP2E1 protein] |
CTD |
PMID:1968335 PMID:8531136 PMID:9143349 |
|
NCBI chr 1:213,511,892...213,522,195
Ensembl chr 1:213,511,874...213,535,542
|
|
G |
Cyp2f4 |
cytochrome P450, family 2, subfamily f, polypeptide 4 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Skatole results in increased expression of CYP2F1 mRNA] |
CTD |
PMID:20187624 |
|
NCBI chr 1:83,933,974...83,947,804
Ensembl chr 1:83,933,942...83,947,821
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [pyridine results in increased expression of CYP3A2 mRNA] |
CTD |
PMID:11181506 |
|
NCBI chr12:11,641,500...11,677,818
Ensembl chr12:11,655,402...11,733,136
|
|
G |
Cyp3a23-3a1 |
cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [pyridine results in increased expression of CYP3A23-3A1 mRNA] |
CTD |
PMID:11181506 |
|
NCBI chr12:11,053,888...11,082,742
Ensembl chr12:11,655,402...11,733,136
|
|
G |
Cyp3a62 |
cytochrome P450, family 3, subfamily a, polypeptide 62 |
decreases expression |
ISO |
Cycloheximide results in decreased expression of CYP3A4 mRNA |
CTD |
PMID:21466820 |
|
NCBI chr12:18,679,809...18,709,397
Ensembl chr12:18,678,594...18,709,397
|
|
G |
Dag1 |
dystroglycan 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of DAG1 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 8:116,980,501...116,993,182
Ensembl chr 8:116,980,497...116,993,193
|
|
G |
Dcn |
decorin |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of DCN mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 7:38,742,250...38,782,282
Ensembl chr 7:38,742,051...38,782,323
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [plumbagin results in increased expression of DDIT3 protein] |
CTD |
PMID:31276663 |
|
NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
|
|
G |
Ddit4 |
DNA-damage-inducible transcript 4 |
increases expression multiple interactions |
EXP |
Cycloheximide results in increased expression of DDIT4 protein [EGF protein co-treated with Cycloheximide] results in increased expression of DDIT4 protein |
CTD |
PMID:22689575 |
|
NCBI chr20:29,509,283...29,511,382
Ensembl chr20:29,509,289...29,511,382
|
|
G |
Deaf1 |
DEAF1 transcription factor |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of DEAF1 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 1:214,283,787...214,317,466
Ensembl chr 1:214,283,790...214,317,466
|
|
G |
Degs1 |
delta(4)-desaturase, sphingolipid 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of DEGS1 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr13:100,665,265...100,672,731
Ensembl chr13:100,666,075...100,672,731
|
|
G |
Dio2 |
iodothyronine deiodinase 2 |
multiple interactions decreases activity |
ISO |
[Cycloheximide co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] inhibits the reaction [2,2',4,4',5-brominated diphenyl ether metabolite results in decreased activity of DIO2 protein]; [Cycloheximide co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in decreased activity of DIO2 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide results in decreased activity of DIO2 protein]; Cycloheximide promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [2,2',4,4',5-brominated diphenyl ether results in decreased activity of DIO2 protein]]; Cycloheximide promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Triiodothyronine, Reverse results in decreased activity of DIO2 protein]]; lactacystin inhibits the reaction [Cycloheximide results in decreased activity of DIO2 protein] |
CTD |
PMID:11425850 PMID:26004626 |
|
NCBI chr 6:114,475,156...114,489,443
Ensembl chr 6:114,476,142...114,476,723
|
|
G |
Dio3 |
iodothyronine deiodinase 3 |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [Hydrogen Peroxide results in increased activity of DIO3 protein] |
CTD |
PMID:18420745 |
|
NCBI chr 6:134,627,278...134,629,139
Ensembl chr 6:134,627,278...134,629,138
|
|
G |
Dnajb5 |
DnaJ heat shock protein family (Hsp40) member B5 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of DNAJB5 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 5:58,393,197...58,402,162
Ensembl chr 5:58,393,233...58,401,870
|
|
G |
Dnase1l3 |
deoxyribonuclease 1-like 3 |
increases expression |
ISO |
Cycloheximide results in increased expression of DNASE1L3 protein |
CTD |
PMID:15118903 |
|
NCBI chr15:18,710,492...18,736,476
Ensembl chr15:18,710,492...18,736,473
|
|
G |
Dnm1l |
dynamin 1-like |
increases expression multiple interactions |
ISO |
Cycloheximide results in increased expression of DNM1L mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of DNM1L mRNA |
CTD |
PMID:19684285 |
|
NCBI chr11:88,830,968...88,882,271
Ensembl chr11:88,830,957...88,880,198
|
|
G |
Dnmt3a |
DNA methyltransferase 3 alpha |
multiple interactions |
EXP |
[Cycloheximide co-treated with FASLG protein] results in decreased expression of DNMT3A mRNA; [Cycloheximide co-treated with FASLG protein] results in decreased expression of DNMT3A protein |
CTD |
PMID:19833194 |
|
NCBI chr 6:28,205,375...28,346,052
Ensembl chr 6:28,235,695...28,340,577
|
|
G |
Edn1 |
endothelin 1 |
multiple interactions |
ISO |
[Cycloheximide co-treated with EDN1 protein] results in increased expression of ADRB2 mRNA |
CTD |
PMID:22483689 |
|
NCBI chr17:22,136,814...22,143,745
Ensembl chr17:22,137,324...22,143,324
|
|
G |
Ednra |
endothelin receptor type A |
multiple interactions |
EXP |
[Dimethyl Sulfoxide co-treated with Cycloheximide] results in decreased expression of EDNRA mRNA; [Dimethyl Sulfoxide co-treated with Cycloheximide] results in decreased expression of EDNRA protein; Cycloheximide inhibits the reaction [Particulate Matter results in increased expression of EDNRA mRNA]; Cycloheximide inhibits the reaction [Particulate Matter results in increased expression of EDNRA protein] |
CTD |
PMID:20561571 |
|
NCBI chr19:33,928,356...33,991,703
Ensembl chr19:33,928,356...33,991,703
|
|
G |
Ednrb |
endothelin receptor type B |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [Dimethyl Sulfoxide results in increased expression of EDNRB mRNA]; Cycloheximide inhibits the reaction [Dimethyl Sulfoxide results in increased expression of EDNRB protein]; Cycloheximide inhibits the reaction [Particulate Matter results in increased expression of EDNRB mRNA]; Cycloheximide inhibits the reaction [Particulate Matter results in increased expression of EDNRB protein]; Cycloheximide inhibits the reaction [Smoke analog results in increased expression of EDNRB protein] |
CTD |
PMID:20561571 PMID:20716444 |
|
NCBI chr15:88,004,775...88,036,354
Ensembl chr15:88,006,977...88,036,354
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
EXP |
[EGF protein co-treated with Cycloheximide] results in increased expression of DDIT4 protein; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Arginine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Asparagine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Isoleucine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Leucine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Lysine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Methionine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Ornithine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Phenylalanine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Tyrosine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Valine]; Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [EGF protein results in increased phosphorylation of RPS6KB1 protein]]; Cycloheximide promotes the reaction [[EGF protein co-treated with Estradiol] results in increased expression of FOS mRNA] |
CTD |
PMID:12632255 PMID:22689575 |
|
NCBI chr 2:68,820,616...68,895,537
|
|
G |
Egfr |
epidermal growth factor receptor |
increases expression multiple interactions |
ISO EXP |
Cycloheximide results in increased expression of EGFR mRNA Cycloheximide promotes the reaction [Arsenic Trioxide results in decreased expression of EGFR protein] Cycloheximide inhibits the reaction [Asbestos, Crocidolite results in increased expression of EGFR protein] |
CTD |
PMID:15228094 PMID:26368632 PMID:30237564 |
|
NCBI chr14:99,919,485...100,104,136
Ensembl chr14:99,919,485...100,098,796
|
|
G |
Egr1 |
early growth response 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [resveratrol results in increased expression of EGR1 mRNA] |
CTD |
PMID:12690110 |
|
NCBI chr18:27,657,903...27,660,101
Ensembl chr18:27,657,628...27,661,429
|
|
G |
Egr2 |
early growth response 2 |
increases expression |
ISO |
Cycloheximide results in increased expression of EGR2 mRNA |
CTD |
PMID:19350554 |
|
NCBI chr20:22,452,170...22,461,018
Ensembl chr20:22,454,463...22,459,025
|
|
G |
Eif2a |
eukaryotic translation initiation factor 2A |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [orlistat results in increased phosphorylation of EIF2A protein] |
CTD |
PMID:17283163 |
|
NCBI chr 2:148,722,343...148,755,781
Ensembl chr 2:148,722,231...148,755,520
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [dimethylarsinous acid results in increased phosphorylation of EIF2AK3 protein] |
CTD |
PMID:22425709 |
|
NCBI chr 4:98,648,513...98,709,695
Ensembl chr 4:98,648,545...98,709,694
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2 subunit alpha |
increases expression increases phosphorylation multiple interactions |
ISO |
Cycloheximide results in increased expression of EIF2S1 mRNA Cycloheximide results in increased phosphorylation of EIF2S1 protein [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of EIF2S1 mRNA |
CTD |
PMID:19684285 PMID:24315374 |
|
NCBI chr 6:102,048,372...102,073,041
Ensembl chr 6:102,048,372...102,073,041
|
|
G |
Eif4e |
eukaryotic translation initiation factor 4E |
multiple interactions |
ISO EXP |
Cycloheximide inhibits the reaction [EIF4E protein modified form inhibits the reaction [sodium arsenite results in decreased expression of CCND1 protein]]; Cycloheximide inhibits the reaction [EIF4E protein modified form inhibits the reaction [sodium arsenite results in decreased expression of ELAVL1 protein]]; Cycloheximide inhibits the reaction [EIF4E protein modified form inhibits the reaction [sodium arsenite results in decreased expression of MCL1 protein]] Cycloheximide inhibits the reaction [EIF4EBP1 protein binds to EIF4E protein] |
CTD |
PMID:22689575 PMID:25923732 |
|
NCBI chr 2:243,819,616...243,853,987
Ensembl chr 2:243,820,661...243,852,631
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [EIF4EBP1 protein binds to EIF4E protein]; Cycloheximide promotes the reaction [EIF4EBP1 protein binds to EIF4G1 protein] |
CTD |
PMID:22689575 |
|
NCBI chr16:68,954,860...68,968,248
Ensembl chr16:68,954,875...68,968,248
|
|
G |
Eif4g1 |
eukaryotic translation initiation factor 4 gamma, 1 |
multiple interactions |
EXP |
Cycloheximide promotes the reaction [EIF4EBP1 protein binds to EIF4G1 protein] |
CTD |
PMID:22689575 |
|
NCBI chr11:83,907,659...83,927,683
Ensembl chr11:83,908,109...83,926,524
|
|
G |
Eif4g3 |
eukaryotic translation initiation factor 4 gamma, 3 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of EIF4G3 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 5:156,343,663...156,564,037
Ensembl chr 5:156,396,695...156,564,037
|
|
G |
Eif5 |
eukaryotic translation initiation factor 5 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in decreased expression of EIF5 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 6:136,002,983...136,011,409
Ensembl chr 6:136,004,214...136,011,406
|
|
G |
Elavl1 |
ELAV like RNA binding protein 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [EIF4E protein modified form inhibits the reaction [sodium arsenite results in decreased expression of ELAVL1 protein]] |
CTD |
PMID:25923732 |
|
NCBI chr12:2,461,502...2,502,432
Ensembl chr12:2,461,502...2,502,432
|
|
G |
Elf4 |
E74 like ETS transcription factor 4 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of ELF4 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr X:135,239,626...135,284,330
Ensembl chr X:135,240,451...135,250,519
|
|
G |
Elk1 |
ETS transcription factor ELK1 |
increases expression multiple interactions |
ISO |
Cycloheximide results in increased expression of ELK1 mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of ELK1 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr X:1,287,875...1,304,822
Ensembl chr X:1,297,099...1,304,822
|
|
G |
Eln |
elastin |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [Okadaic Acid results in decreased expression of ELN mRNA] |
CTD |
PMID:8997264 |
|
NCBI chr12:24,978,478...25,021,864
Ensembl chr12:24,978,483...25,021,863
|
|
G |
Elovl3 |
ELOVL fatty acid elongase 3 |
decreases expression multiple interactions |
ISO |
Cycloheximide results in decreased expression of ELOVL3 mRNA Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of ELOVL3 mRNA] |
CTD |
PMID:17726147 |
|
NCBI chr 1:265,883,353...265,887,181
Ensembl chr 1:265,883,355...265,887,226
|
|
G |
Enc1 |
ectodermal-neural cortex 1 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in decreased expression of ENC1 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 2:28,049,217...28,061,023
Ensembl chr 2:28,049,217...28,061,029
|
|
G |
Endog |
endonuclease G |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of ENDOG mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 3:8,741,833...8,744,414
Ensembl chr 3:8,741,766...8,744,592
|
|
G |
Epas1 |
endothelial PAS domain protein 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [cobaltous chloride results in increased expression of EPAS1 protein]; Cycloheximide inhibits the reaction [Oxygen deficiency results in increased expression of EPAS1 protein] |
CTD |
PMID:23958427 |
|
NCBI chr 6:10,306,508...10,385,239
Ensembl chr 6:10,306,405...10,387,265
|
|
G |
Epo |
erythropoietin |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Oxygen deficiency results in increased expression of EPO mRNA] |
CTD |
PMID:10756076 |
|
NCBI chr12:22,274,828...22,278,268
Ensembl chr12:22,274,828...22,278,266
|
|
G |
Epyc |
epiphycan |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of EPYC mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 7:38,897,278...38,934,989
Ensembl chr 7:38,897,278...38,934,985
|
|
G |
Erbb2 |
erb-b2 receptor tyrosine kinase 2 |
multiple interactions increases degradation decreases expression |
ISO |
[Cycloheximide co-treated with Estradiol] results in decreased expression of ERBB2 mRNA; Curcumin analog promotes the reaction [Cycloheximide results in increased degradation of ERBB2 protein]; PA2G4 protein promotes the reaction [Cycloheximide results in decreased expression of ERBB2 protein] Cycloheximide results in decreased expression of ERBB2 mRNA; Cycloheximide results in decreased expression of ERBB2 protein |
CTD |
PMID:15072547 PMID:15228094 PMID:20379846 PMID:25866362 |
|
NCBI chr10:86,367,596...86,391,728
Ensembl chr10:86,367,596...86,391,728
|
|
G |
Erbb3 |
erb-b2 receptor tyrosine kinase 3 |
decreases expression |
ISO |
Cycloheximide results in decreased expression of ERBB3 mRNA |
CTD |
PMID:15228094 |
|
NCBI chr 7:2,989,202...3,010,610
Ensembl chr 7:2,989,340...3,010,350
|
|
G |
Ereg |
epiregulin |
increases expression |
ISO |
Cycloheximide results in increased expression of EREG mRNA |
CTD |
PMID:15228094 |
|
NCBI chr14:18,577,620...18,591,395
Ensembl chr14:18,576,355...18,591,394
|
|
G |
Ern1 |
endoplasmic reticulum to nucleus signaling 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Butyric Acid results in increased expression of ERN1 protein] |
CTD |
PMID:26784903 |
|
NCBI chr10:94,588,555...94,682,072
Ensembl chr10:94,588,555...94,681,914
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions decreases expression |
ISO |
bisphenol A promotes the reaction [Cycloheximide results in decreased expression of ESR1 protein]; Estradiol promotes the reaction [Cycloheximide results in decreased expression of ESR1 protein]; naringenin inhibits the reaction [Cycloheximide results in decreased expression of ESR1 protein] |
CTD |
PMID:24586459 |
|
NCBI chr 1:41,192,029...41,594,799
Ensembl chr 1:41,192,824...41,594,796
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions |
ISO |
Cycloheximide promotes the reaction [Estradiol results in increased expression of ESR2 mRNA]; Tetrachlorodibenzodioxin inhibits the reaction [Cycloheximide promotes the reaction [Estradiol results in increased expression of ESR2 mRNA]] |
CTD |
PMID:15207704 |
|
NCBI chr 6:99,163,953...99,214,711
Ensembl chr 6:99,164,357...99,214,251
|
|
G |
Ext2 |
exostosin glycosyltransferase 2 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of EXT2 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 3:82,602,784...82,734,557
Ensembl chr 3:82,602,785...82,734,533
|
|
G |
F12 |
coagulation factor XII |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of F12 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr17:9,736,577...9,744,420
Ensembl chr17:9,736,577...9,744,420
|
|
G |
F2 |
coagulation factor II |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Simvastatin results in decreased activity of F2 protein] |
CTD |
PMID:14630613 |
|
NCBI chr 3:80,529,468...80,542,993
Ensembl chr 3:80,529,428...80,543,031
|
|
G |
F3 |
coagulation factor III, tissue factor |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tretinoin results in decreased expression of F3 mRNA] |
CTD |
PMID:11876987 |
|
NCBI chr 2:225,310,686...225,322,281
Ensembl chr 2:225,310,624...225,322,272
|
|
G |
Fas |
Fas cell surface death receptor |
multiple interactions increases response to substance |
ISO |
Cycloheximide promotes the reaction [FAS protein results in increased activity of CASP3 protein]; Cycloheximide promotes the reaction [FAS protein results in increased activity of CASP7 protein]; Cycloheximide promotes the reaction [FAS protein results in increased activity of CASP8 protein] Cycloheximide results in increased susceptibility to FAS protein |
CTD |
PMID:8932996 PMID:12760867 |
|
NCBI chr 1:252,589,785...252,624,790
Ensembl chr 1:252,589,785...252,624,790
|
|
G |
Faslg |
Fas ligand |
multiple interactions |
ISO EXP |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of FASLG mRNA] [Cycloheximide co-treated with FASLG protein] results in decreased expression of DNMT3A mRNA; [Cycloheximide co-treated with FASLG protein] results in decreased expression of DNMT3A protein |
CTD |
PMID:11007951 PMID:19833194 |
|
NCBI chr13:79,696,811...79,717,581
Ensembl chr13:79,698,445...79,705,705
|
|
G |
Fasn |
fatty acid synthase |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Calcitriol results in decreased expression of FASN mRNA] |
CTD |
PMID:12798352 |
|
NCBI chr10:109,987,735...110,005,901
Ensembl chr10:109,987,735...110,005,901
|
|
G |
Fbl |
fibrillarin |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of FBL mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 1:85,103,519...85,112,619
Ensembl chr 1:85,103,519...85,112,619
|
|
G |
Fbxw7 |
F-box and WD repeat domain containing 7 |
multiple interactions |
ISO |
Cycloheximide promotes the reaction [FBXW7 protein binds to and results in decreased expression of RICTOR protein] |
CTD |
PMID:25897075 |
|
NCBI chr 2:184,230,191...184,309,805
Ensembl chr 2:184,231,260...184,309,664
|
|
G |
Fga |
fibrinogen alpha chain |
decreases expression |
EXP |
Cycloheximide results in decreased expression of FGA protein |
CTD |
PMID:444225 |
|
NCBI chr 2:181,997,562...182,013,726
Ensembl chr 2:182,006,242...182,013,763
|
|
G |
Fgb |
fibrinogen beta chain |
decreases expression |
EXP |
Cycloheximide results in decreased expression of FGB protein |
CTD |
PMID:444225 |
|
NCBI chr 2:182,028,044...182,035,026
Ensembl chr 2:182,027,115...182,038,178
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [Dinoprost affects the localization of FGF2 protein]; Cycloheximide promotes the reaction [FGF2 protein results in increased expression of SERPINE1 mRNA] |
CTD |
PMID:9798919 PMID:15654655 |
|
NCBI chr 2:124,081,072...124,134,133
Ensembl chr 2:124,081,072...124,134,681
|
|
G |
Fgfr1 |
Fibroblast growth factor receptor 1 |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [Triiodothyronine results in increased expression of FGFR1 mRNA] |
CTD |
PMID:12805413 |
|
NCBI chr16:71,265,390...71,319,046
Ensembl chr16:71,266,248...71,319,449
|
|
G |
Fgl2 |
fibrinogen-like 2 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of FGL2 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 4:10,323,598...10,329,241
Ensembl chr 4:10,323,607...10,329,241
|
|
G |
Fhit |
fragile histidine triad diadenosine triphosphatase |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of FHIT mRNA |
CTD |
PMID:19684285 |
|
NCBI chr15:15,697,292...16,862,873
|
|
G |
Fhl1 |
four and a half LIM domains 1 |
multiple interactions |
EXP |
Cycloheximide promotes the reaction [25-hydroxycholesterol results in increased expression of FHL1 mRNA] |
CTD |
PMID:17161435 |
|
NCBI chr X:159,112,516...159,172,528
Ensembl chr X:159,112,880...159,172,524
|
|
G |
Fmo3 |
flavin containing dimethylaniline monoxygenase 3 |
increases expression |
ISO |
Cycloheximide results in increased expression of FMO3 mRNA |
CTD |
PMID:20570689 |
|
NCBI chr13:80,837,418...80,856,214
Ensembl chr13:80,837,420...80,862,963
|
|
G |
Fmr1 |
FMRP translational regulator 1 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of FMR1 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr X:154,684,924...154,722,369
Ensembl chr X:154,684,935...154,722,314
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases expression |
ISO EXP |
Cycloheximide inhibits the reaction [Estradiol results in increased expression of FOS protein]; Cycloheximide inhibits the reaction [Genistein results in increased expression of FOS protein]; Cycloheximide inhibits the reaction [Quercetin results in increased expression of FOS protein]; Cycloheximide promotes the reaction [Cadmium Chloride results in increased expression of FOS mRNA] Cycloheximide results in increased expression of FOS mRNA Cycloheximide inhibits the reaction [NGF protein results in increased expression of FOS protein] [Cycloheximide co-treated with Cadmium] results in increased expression of FOS mRNA; Cadmium Chloride promotes the reaction [Cycloheximide results in increased expression of FOS mRNA]; Cycloheximide inhibits the reaction [Hydrogen Peroxide results in increased expression of FOS protein]; Cycloheximide promotes the reaction [[EGF protein co-treated with Estradiol] results in increased expression of FOS mRNA]; Cycloheximide promotes the reaction [Cadmium Chloride results in increased expression of FOS mRNA]; Dactinomycin inhibits the reaction [[Cycloheximide co-treated with Cadmium] results in increased expression of FOS mRNA] |
CTD |
PMID:1696944 PMID:9094091 PMID:9417049 PMID:9650640 PMID:12632255 PMID:15090535 PMID:15136564 PMID:20495008 |
|
NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
|
|
G |
Frk |
fyn-related Src family tyrosine kinase |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of FRK mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr20:41,266,408...41,383,731
Ensembl chr20:41,266,566...41,383,424
|
|
G |
Fst |
follistatin |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of FST mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 2:46,537,589...46,544,813
Ensembl chr 2:46,538,700...46,544,457
|
|
G |
Fut4 |
fucosyltransferase 4 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of FUT4 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 8:13,258,768...13,262,729
Ensembl chr 8:13,258,768...13,262,729
|
|
G |
Fzd7 |
frizzled class receptor 7 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of FZD7 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 9:66,305,731...66,308,550
Ensembl chr 9:66,305,731...66,308,550
|
|
G |
G6pd |
glucose-6-phosphate dehydrogenase |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [Isoproterenol results in increased activity of G6PD protein] |
CTD |
PMID:1978808 |
|
NCBI chr X:156,274,800...156,293,935
Ensembl chr X:156,274,800...156,293,926
|
|
G |
Galnt1 |
polypeptide N-acetylgalactosaminyltransferase 1 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in decreased expression of GALNT1 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr18:16,141,062...16,187,271
Ensembl chr18:16,146,447...16,185,496
|
|
G |
Gas1 |
growth arrest-specific 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of GAS1 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr17:4,846,116...4,849,350
Ensembl chr17:4,846,789...4,847,940
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
multiple interactions |
ISO EXP |
Cycloheximide inhibits the reaction [arsenite results in increased activity of [GCLC protein binds to GCLM protein]]; Cycloheximide inhibits the reaction [arsenite results in increased expression of [GCLC protein binds to GCLM protein]]; Cycloheximide inhibits the reaction [arsenite results in increased expression of GCLC mRNA]; Cycloheximide inhibits the reaction [diphenylarsinic acid results in increased expression of GCLC protein] Cycloheximide inhibits the reaction [notoginsenoside R1 results in increased expression of GCLC protein] |
CTD |
PMID:17628625 PMID:19328227 PMID:24437944 |
|
NCBI chr 8:85,059,051...85,097,471
Ensembl chr 8:85,059,051...85,097,468
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [arsenite results in increased activity of [GCLC protein binds to GCLM protein]]; Cycloheximide inhibits the reaction [arsenite results in increased expression of [GCLC protein binds to GCLM protein]]; Cycloheximide inhibits the reaction [arsenite results in increased expression of GCLM mRNA] |
CTD |
PMID:19328227 |
|
NCBI chr 2:225,827,504...225,847,876
Ensembl chr 2:225,827,504...225,847,874
|
|
G |
Gdf15 |
growth differentiation factor 15 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [trichostatin A affects the expression of GDF15 mRNA]; Cycloheximide inhibits the reaction [trichostatin A affects the expression of GDF15 protein]; Cycloheximide inhibits the reaction [troglitazone results in increased expression of GDF15 mRNA] |
CTD |
PMID:14662774 PMID:18801729 |
|
NCBI chr16:20,555,395...20,557,978
Ensembl chr16:20,555,395...20,557,978
|
|
G |
Gpaa1 |
glycosylphosphatidylinositol anchor attachment 1 |
increases expression multiple interactions |
ISO |
Cycloheximide results in increased expression of GPAA1 mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of GPAA1 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 7:117,394,367...117,397,950
Ensembl chr 7:117,394,372...117,397,956
|
|
G |
Gpr37 |
G protein-coupled receptor 37 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of GPR37 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 4:51,822,163...51,844,228
Ensembl chr 4:51,822,153...51,844,331
|
|
G |
Grm5 |
glutamate metabotropic receptor 5 |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [Dextroamphetamine results in increased expression of GRM5 mRNA]; Cycloheximide inhibits the reaction [Dextroamphetamine results in increased expression of GRM5 protein] |
CTD |
PMID:11665859 |
|
NCBI chr 1:151,207,846...151,785,038
Ensembl chr 1:151,439,409...151,783,392
|
|
G |
Grn |
granulin precursor |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in decreased expression of GRN mRNA |
CTD |
PMID:19684285 |
|
NCBI chr10:90,377,103...90,383,207
Ensembl chr10:90,376,933...90,383,205
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of GSK3B mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr11:65,060,884...65,208,842
Ensembl chr11:65,066,235...65,209,268
|
|
G |
Gsta2 |
glutathione S-transferase alpha 2 |
multiple interactions decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide inhibits the reaction [Lead results in increased expression of GSTA1 mRNA]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide inhibits the reaction [Mercury results in increased expression of GSTA1 mRNA]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of GSTA1 mRNA]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide promotes the reaction [Copper results in decreased expression of GSTA1 mRNA]]; Cycloheximide inhibits the reaction [Lead results in increased expression of GSTA1 mRNA]; Cycloheximide inhibits the reaction [Mercury results in increased expression of GSTA1 mRNA]; Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of GSTA1 mRNA]; Cycloheximide promotes the reaction [Copper results in decreased expression of GSTA1 mRNA] Cycloheximide results in decreased expression of GSTA1 mRNA |
CTD |
PMID:16243960 |
|
NCBI chr 8:85,640,081...85,645,621
|
|
G |
Gsta6 |
glutathione S-transferase alpha 6 |
multiple interactions decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide inhibits the reaction [Lead results in increased expression of GSTA1 mRNA]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide inhibits the reaction [Mercury results in increased expression of GSTA1 mRNA]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of GSTA1 mRNA]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide promotes the reaction [Copper results in decreased expression of GSTA1 mRNA]]; Cycloheximide inhibits the reaction [Lead results in increased expression of GSTA1 mRNA]; Cycloheximide inhibits the reaction [Mercury results in increased expression of GSTA1 mRNA]; Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of GSTA1 mRNA]; Cycloheximide promotes the reaction [Copper results in decreased expression of GSTA1 mRNA] Cycloheximide results in decreased expression of GSTA1 mRNA |
CTD |
PMID:16243960 |
|
NCBI chr 9:27,475,273...27,533,939
Ensembl chr 9:27,475,273...27,511,176
|
|
G |
Hbegf |
heparin-binding EGF-like growth factor |
increases expression |
ISO |
Cycloheximide results in increased expression of HBEGF mRNA |
CTD |
PMID:15228094 |
|
NCBI chr18:29,330,302...29,340,185
Ensembl chr18:29,329,764...29,340,403
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
increases degradation decreases expression multiple interactions |
ISO EXP |
Cycloheximide results in increased degradation of HIF1A protein Cycloheximide results in decreased expression of HIF1A protein Cycloheximide promotes the reaction [methylmercuric chloride results in decreased expression of HIF1A protein] [Cycloheximide co-treated with cobaltous chloride] results in decreased expression of HIF1A protein; [Cycloheximide co-treated with INS protein] results in decreased expression of HIF1A protein; [Oxygen deficiency co-treated with Cycloheximide] affects the expression of HIF1A protein; Cycloheximide inhibits the reaction [[cobaltous chloride co-treated with Glucose] results in increased expression of HIF1A protein]; Cycloheximide inhibits the reaction [MLN7243 results in increased sumoylation of HIF1A protein]; Cycloheximide inhibits the reaction [Oxygen deficiency results in increased expression of HIF1A protein]; Cycloheximide inhibits the reaction [Quercetin results in increased expression of HIF1A protein]; Cycloheximide inhibits the reaction [sodium arsenite results in increased expression of HIF1A protein]; Cycloheximide inhibits the reaction [sodium arsenite results in increased stability of HIF1A protein]; Cycloheximide inhibits the reaction [zinc chloride results in increased expression of HIF1A protein alternative form]; Cycloheximide promotes the reaction [Cobalt results in increased expression of HIF1A protein]; Cycloheximide promotes the reaction [nickel chloride results in increased expression of HIF1A protein]; genipin affects the reaction [[Oxygen deficiency co-treated with Cycloheximide] affects the expression of HIF1A protein]; L-4F peptide promotes the reaction [[Cycloheximide co-treated with cobaltous chloride] results in decreased expression of HIF1A protein]; L-4F peptide promotes the reaction [[Cycloheximide co-treated with INS protein] results in decreased expression of HIF1A protein]; scutellarin inhibits the reaction [[cobaltous chloride co-treated with Glucose co-treated with Cycloheximide] results in decreased expression of HIF1A protein]; scutellarin promotes the reaction [Cycloheximide inhibits the reaction [[cobaltous chloride co-treated with Glucose] results in increased expression of HIF1A protein]] Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of HIF1A protein] |
CTD |
PMID:11641398 PMID:11739637 PMID:19958256 PMID:20524035 PMID:22537771 PMID:23593480 PMID:24188932 PMID:24221993 PMID:24497960 PMID:25192544 PMID:29630948 PMID:30266538 PMID:31285264 PMID:31850806 |
|
NCBI chr 6:96,810,868...96,856,303
Ensembl chr 6:96,810,907...96,856,052
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions decreases expression |
ISO EXP |
Cycloheximide inhibits the reaction [Curcumin results in increased expression of HMOX1 protein]; Cycloheximide inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 mRNA]; Cycloheximide inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 protein]; Cycloheximide inhibits the reaction [Oxygen results in increased expression of HMOX1 mRNA]; Cycloheximide inhibits the reaction [Plant Extracts results in increased expression of HMOX1 protein]; Cycloheximide inhibits the reaction [resveratrol results in increased expression of HMOX1 mRNA]; Cycloheximide inhibits the reaction [resveratrol results in increased expression of HMOX1 protein]; Cycloheximide inhibits the reaction [tricarbonyldichlororuthenium (II) dimer results in increased expression of HMOX1 protein]; Cycloheximide results in decreased susceptibility to [surfactin peptide results in increased expression of HMOX1 protein] Cycloheximide inhibits the reaction [cobaltous chloride results in increased expression of HMOX1 mRNA]; Cycloheximide inhibits the reaction [notoginsenoside R1 results in increased expression of HMOX1 protein]; Cycloheximide inhibits the reaction [Quercetin results in increased expression of HMOX1 protein]; Cycloheximide inhibits the reaction [resveratrol results in increased expression of HMOX1 protein]; Cycloheximide inhibits the reaction [sodium arsenite results in increased expression of HMOX1 protein] Cycloheximide results in decreased expression of HMOX1 protein Cycloheximide inhibits the reaction [Cadmium Chloride results in increased expression of HMOX1 mRNA]; Cycloheximide inhibits the reaction [fisetin results in increased expression of HMOX1 protein]; Cycloheximide inhibits the reaction [puerarin results in increased expression of HMOX1 protein]; Cycloheximide inhibits the reaction [Quercetin results in increased expression of HMOX1 protein]; Cycloheximide inhibits the reaction [Triterpenes analog results in increased expression of HMOX1 protein] |
CTD |
PMID:9747510 PMID:12441344 PMID:12472888 PMID:15118350 PMID:15588712 PMID:15876423 PMID:15965080 PMID:16647178 PMID:17002867 PMID:18357586 PMID:19781563 PMID:20060010 PMID:20833156 PMID:21840424 PMID:24255720 PMID:24437944 PMID:25239868 PMID:26385185 PMID:30076913 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Hnrnph2 |
heterogeneous nuclear ribonucleoprotein H2 |
increases expression |
ISO |
Cycloheximide results in increased expression of HNRNPH2 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr X:105,417,603...105,423,531
Ensembl chr X:105,419,285...105,422,861
|
|
G |
Hnrnpk |
heterogeneous nuclear ribonucleoprotein K |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [Glycine results in increased expression of HNRNPK protein] |
CTD |
PMID:24990929 |
|
NCBI chr17:6,664,730...6,676,753
Ensembl chr17:6,665,659...6,676,654
|
|
G |
Hsd11b2 |
hydroxysteroid 11-beta dehydrogenase 2 |
multiple interactions |
ISO |
Cycloheximide promotes the reaction [Bexarotene results in increased expression of HSD11B2 mRNA]; Cycloheximide promotes the reaction [tributyltin results in increased expression of HSD11B2 mRNA]; Cycloheximide promotes the reaction [triphenyltin chloride results in increased expression of HSD11B2 mRNA] |
CTD |
PMID:31927052 |
|
NCBI chr19:37,476,083...37,481,326
Ensembl chr19:37,476,095...37,481,307
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
EXP ISO |
Cycloheximide inhibits the reaction [GIF 0010 results in increased expression of HSPA5 mRNA]; Cycloheximide inhibits the reaction [lead acetate results in increased expression of HSPA5 protein]; Cycloheximide inhibits the reaction [Mercuric Chloride results in increased expression of HSPA5 protein] Cycloheximide inhibits the reaction [Butyric Acid results in increased expression of HSPA5 protein]; Cycloheximide inhibits the reaction [plumbagin results in increased expression of HSPA5 protein] |
CTD |
PMID:9742210 PMID:17915553 PMID:26784903 PMID:31276663 |
|
NCBI chr 3:13,838,304...13,842,763
Ensembl chr 3:13,838,304...13,842,762
|
|
G |
Htatip2 |
HIV-1 Tat interactive protein 2 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of HTATIP2 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 1:105,094,272...105,109,459
Ensembl chr 1:105,094,411...105,109,461
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions decreases expression |
ISO |
Cycloheximide inhibits the reaction [IFNG protein results in increased expression of ICAM1 protein] Cycloheximide results in decreased expression of ICAM1 protein |
CTD |
PMID:16087364 |
|
NCBI chr 8:22,035,287...22,047,049
Ensembl chr 8:22,035,256...22,047,059
|
|
G |
Ier3 |
immediate early response 3 |
multiple interactions |
ISO |
[afimoxifene co-treated with Cycloheximide] results in increased expression of IER3 mRNA |
CTD |
PMID:16849584 |
|
NCBI chr20:3,438,798...3,440,002
Ensembl chr20:3,438,798...3,440,769
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
[Cycloheximide co-treated with IFNG protein] results in increased expression of PLAUR mRNA; Cycloheximide inhibits the reaction [IFNG protein results in increased expression of ICAM1 protein]; Cycloheximide inhibits the reaction [IFNG protein results in increased expression of TJP1 protein] |
CTD |
PMID:12070711 PMID:16087364 |
|
NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
|
|
G |
Ift27 |
intraflagellar transport 27 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of IFT27 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 7:119,393,384...119,409,710
Ensembl chr 7:119,393,384...119,409,710
|
|
G |
Igf1 |
insulin-like growth factor 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [IGF1 protein affects the metabolism of 1,2-diacylglycerol] IGF1 protein inhibits the reaction [Cycloheximide results in decreased expression of CDKN1A protein] |
CTD |
PMID:2120207 PMID:26687534 |
|
NCBI chr 7:28,412,123...28,491,815
Ensembl chr 7:28,412,198...28,486,609
|
|
G |
Igfbp4 |
insulin-like growth factor binding protein 4 |
increases expression multiple interactions |
ISO |
Cycloheximide results in increased expression of IGFBP4 mRNA [Cycloheximide co-treated with Estradiol] results in increased expression of IGFBP4 mRNA |
CTD |
PMID:15072547 |
|
NCBI chr10:86,950,555...86,962,563
Ensembl chr10:86,950,557...86,962,578
|
|
G |
Il10 |
interleukin 10 |
multiple interactions decreases response to substance increases expression |
ISO EXP |
Cycloheximide inhibits the reaction [Lipopolysaccharides results in increased expression of IL10 mRNA] IL10 protein results in decreased susceptibility to Cycloheximide Cycloheximide results in increased expression of IL10 mRNA |
CTD |
PMID:19395591 PMID:22183712 |
|
NCBI chr13:47,738,933...47,743,392
Ensembl chr13:47,739,526...47,743,392
|
|
G |
Il17a |
interleukin 17A |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Glucose results in increased secretion of IL17A protein] |
CTD |
PMID:18310510 |
|
NCBI chr 9:26,841,299...26,844,786
Ensembl chr 9:26,841,299...26,844,786
|
|
G |
Il18 |
interleukin 18 |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [Aldosterone results in increased expression of IL18 mRNA] |
CTD |
PMID:18660453 |
|
NCBI chr 8:55,009,666...55,016,286
Ensembl chr 8:54,993,859...55,016,299
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions increases expression |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of IL1A mRNA Cycloheximide results in increased expression of IL1A mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 3:121,824,712...121,836,122
Ensembl chr 3:121,825,412...121,836,086
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions increases expression |
ISO EXP |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of IL1B mRNA; Cycloheximide inhibits the reaction [CXCL8 protein affects the secretion of IL1B protein]; Cycloheximide inhibits the reaction [Dinoprostone promotes the reaction [IL1B protein results in increased expression of PTGS2 protein]]; Cycloheximide inhibits the reaction [IL1B protein results in increased expression of PTGS2 protein]; Cycloheximide inhibits the reaction [IL1B results in increased secretion of CSF2 protein]; Cycloheximide inhibits the reaction [tetrachlorobenzoquinone results in increased expression of IL1B protein]; Cycloheximide inhibits the reaction [tetrachlorobenzoquinone results in increased secretion of IL1B protein modified form] Cycloheximide promotes the reaction [IL1B protein results in increased expression of PTGS2 mRNA] Cycloheximide results in increased expression of IL1B mRNA |
CTD |
PMID:8071060 PMID:9606035 PMID:11112151 PMID:11286988 PMID:19684285 PMID:26901245 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il5 |
interleukin 5 |
decreases expression multiple interactions |
ISO |
Cycloheximide results in decreased expression of IL5 protein TO-901317 inhibits the reaction [Cycloheximide results in decreased expression of IL5 protein] |
CTD |
PMID:23150660 |
|
NCBI chr10:39,066,716...39,069,587
Ensembl chr10:39,066,716...39,069,587
|
|
G |
Il6 |
interleukin 6 |
multiple interactions increases expression decreases secretion increases secretion |
ISO |
Cycloheximide inhibits the reaction [CXCL8 protein affects the secretion of IL6 protein]; TNF protein promotes the reaction [Cycloheximide results in increased expression of IL6 mRNA]; TNF protein promotes the reaction [Cycloheximide results in increased secretion of IL6 protein]; Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of IL6 mRNA]]; Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased secretion of IL6 protein]] Cycloheximide results in decreased secretion of IL6 protein |
CTD |
PMID:8071060 PMID:11216681 PMID:12185005 PMID:21146893 PMID:24771768 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Il6st |
interleukin 6 cytokine family signal transducer |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of IL6ST mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 2:44,279,199...44,319,427
Ensembl chr 2:44,289,393...44,314,944
|
|
G |
Ins2 |
insulin 2 |
multiple interactions |
ISO |
[Cycloheximide co-treated with INS protein] results in decreased expression of HIF1A protein; L-4F peptide promotes the reaction [[Cycloheximide co-treated with INS protein] results in decreased expression of HIF1A protein] |
CTD |
PMID:22537771 |
|
NCBI chr 1:215,856,967...215,858,034
Ensembl chr 1:215,856,971...215,858,034
|
|
G |
Iqgap1 |
IQ motif containing GTPase activating protein 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of IQGAP1 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 1:142,525,041...142,615,673
Ensembl chr 1:142,525,046...142,615,673
|
|
G |
Irs1 |
insulin receptor substrate 1 |
decreases expression multiple interactions |
ISO |
Cycloheximide results in decreased expression of IRS1 mRNA [Cycloheximide co-treated with Estradiol] results in increased expression of IRS1 mRNA |
CTD |
PMID:15072547 |
|
NCBI chr 9:88,033,668...88,086,488
Ensembl chr 9:88,033,668...88,086,488
|
|
G |
Itgb3 |
integrin subunit beta 3 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of ITGB3 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr10:92,667,869...92,783,413
Ensembl chr10:92,667,869...92,783,410
|
|
G |
Itgb6 |
integrin subunit beta 6 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of ITGB6 mRNA]; Cycloheximide inhibits the reaction [TGFB1 protein results in increased expression of ITGB6 mRNA] |
CTD |
PMID:11007951 PMID:21303922 |
|
NCBI chr 3:46,652,624...46,775,362
Ensembl chr 3:46,652,623...46,726,958
|
|
G |
Itpk1 |
inositol-tetrakisphosphate 1-kinase |
multiple interactions |
ISO |
ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased activity of CASP9 protein]; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of and results in increased activity of CASP3 protein]; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of and results in increased activity of CASP8 protein]; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of BID protein]; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of PARP1 protein]; ITPK1 mutant form promotes the reaction [[Cycloheximide co-treated with TNF protein] results in increased cleavage of BID protein]; ITPK1 mutant form promotes the reaction [[Cycloheximide co-treated with TNF protein] results in increased cleavage of PARP1 protein]; ITPK1 mutant form results in increased susceptibility to [Cycloheximide co-treated with TNF protein] |
CTD |
PMID:12925536 |
|
NCBI chr 6:126,448,920...126,582,188
Ensembl chr 6:126,450,139...126,582,134
|
|
G |
Itpr1 |
inositol 1,4,5-trisphosphate receptor, type 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Ethanol results in increased expression of ITPR1 mRNA]; Cycloheximide inhibits the reaction [linsidomine results in increased expression of ITPR1 mRNA]; Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of ITPR1 mRNA] |
CTD |
PMID:11007951 PMID:17241155 |
|
NCBI chr 4:140,247,297...140,580,749
Ensembl chr 4:140,247,313...140,580,748
|
|
G |
Ivns1abp |
influenza virus NS1A binding protein |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Doxorubicin results in decreased expression of IVNS1ABP mRNA] |
CTD |
PMID:17016628 |
|
NCBI chr13:68,702,970...68,722,472
Ensembl chr13:68,702,820...68,722,472
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
increases stability increases phosphorylation multiple interactions |
EXP ISO |
Cycloheximide results in increased stability of JUN protein Cycloheximide results in increased phosphorylation of JUN protein Cycloheximide promotes the reaction [Cadmium results in increased expression of JUN mRNA] Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of JUN protein] |
CTD |
PMID:1696944 PMID:9751194 PMID:12169099 PMID:23593480 |
|
NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277
|
|
G |
Kank1 |
KN motif and ankyrin repeat domains 1 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of KANK1 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 1:243,201,073...243,398,531
Ensembl chr 1:243,276,403...243,398,536
|
|
G |
Kng2 |
kininogen 2 |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [KNG1 protein results in increased phosphorylation of MAPK1 protein]; Cycloheximide inhibits the reaction [KNG1 protein results in increased phosphorylation of MAPK3 protein]; Cycloheximide inhibits the reaction [KNG1 protein results in increased phosphorylation of PTGS2 protein]; Cycloheximide inhibits the reaction [KNG1 protein results in increased secretion of TAC1 protein] |
CTD |
PMID:16696851 |
|
NCBI chr11:81,509,185...81,516,759
|
|
G |
Kras |
KRAS proto-oncogene, GTPase |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of KRAS mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 4:179,482,562...179,515,483
Ensembl chr 4:179,486,105...179,515,558
|
|
G |
Kremen1 |
kringle containing transmembrane protein 1 |
affects response to substance |
ISO |
KREMEN1 gene SNP affects the susceptibility to Cycloheximide |
CTD |
PMID:25622337 |
|
NCBI chr14:85,441,209...85,503,661
Ensembl chr14:85,438,707...85,484,275
|
|
G |
Krt13 |
keratin 13 |
multiple interactions |
ISO |
[afimoxifene co-treated with Cycloheximide] results in increased expression of KRT13 mRNA |
CTD |
PMID:16849584 |
|
NCBI chr10:88,032,130...88,036,040
Ensembl chr10:88,032,130...88,036,040
|
|
G |
Krtcap2 |
keratinocyte associated protein 2 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of KRTCAP2 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 2:188,561,548...188,565,544
Ensembl chr 2:188,561,429...188,565,544
|
|
G |
Lck |
LCK proto-oncogene, Src family tyrosine kinase |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of LCK mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 5:147,750,976...147,779,627
Ensembl chr 5:147,750,973...147,761,983
|
|
G |
Ldlr |
low density lipoprotein receptor |
multiple interactions decreases expression |
ISO |
Cycloheximide inhibits the reaction [Quercetin results in increased expression of LDLR protein] Cycloheximide results in decreased expression of LDLR protein |
CTD |
PMID:22388943 |
|
NCBI chr 8:22,750,425...22,773,305
Ensembl chr 8:22,750,336...22,774,903
|
|
G |
Lep |
leptin |
multiple interactions |
ISO |
LEP protein inhibits the reaction [Cycloheximide results in decreased expression of LEPR protein] |
CTD |
PMID:31199479 |
|
NCBI chr 4:56,337,695...56,351,818
Ensembl chr 4:56,337,695...56,351,818
|
|
G |
Lepr |
leptin receptor |
multiple interactions decreases expression |
ISO |
LEP protein inhibits the reaction [Cycloheximide results in decreased expression of LEPR protein] |
CTD |
PMID:31199479 |
|
NCBI chr 5:120,503,475...120,682,281
Ensembl chr 5:120,564,645...120,682,221
|
|
G |
Lgals3 |
galectin 3 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in increased expression of LGALS3 protein] |
CTD |
PMID:21821001 |
|
NCBI chr15:24,153,602...24,165,537
Ensembl chr15:24,141,651...24,165,537
|
|
G |
Lhb |
luteinizing hormone subunit beta |
multiple interactions |
EXP |
Cycloheximide promotes the reaction [LHB protein results in increased expression of NR4A1 mRNA] |
CTD |
PMID:11416027 |
|
NCBI chr 1:101,409,992...101,413,725
Ensembl chr 1:101,410,019...101,413,724
|
|
G |
Lmo7 |
LIM domain 7 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of LMO7 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr15:86,242,911...86,458,512
Ensembl chr15:86,243,148...86,457,739
|
|
G |
Lpxn |
leupaxin |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of LPXN mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 1:229,642,437...229,674,129
Ensembl chr 1:229,642,412...229,674,134
|
|
G |
Maf1 |
MAF1 homolog, negative regulator of RNA polymerase III |
increases degradation multiple interactions |
ISO |
Cycloheximide results in increased degradation of MAF1 protein Bortezomib inhibits the reaction [Cycloheximide results in increased degradation of MAF1 protein]; CUL2 protein affects the reaction [Cycloheximide results in increased degradation of MAF1 protein]; Cycloheximide inhibits the reaction [Sirolimus results in increased expression of MAF1 protein]; PSMD1 protein affects the reaction [Cycloheximide results in increased degradation of MAF1 protein] |
CTD |
PMID:31645432 |
|
NCBI chr 7:117,417,643...117,420,722
Ensembl chr 7:117,417,687...117,420,719
|
|
G |
Map2k1 |
mitogen activated protein kinase kinase 1 |
multiple interactions increases activity |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Cycloheximide results in increased expression of MAP2K1 mRNA] Cycloheximide results in increased activity of MAP2K1 protein |
CTD |
PMID:23237828 |
|
NCBI chr 8:69,134,218...69,722,573
Ensembl chr 8:69,134,223...69,164,758
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation multiple interactions |
ISO EXP |
Cycloheximide results in increased phosphorylation of MAPK1 protein Cycloheximide inhibits the reaction [KNG1 protein results in increased phosphorylation of MAPK1 protein]; Cycloheximide promotes the reaction [[sodium arsenite co-treated with Hydrogen Peroxide] results in increased phosphorylation of MAPK1 protein] Cycloheximide inhibits the reaction [Cyclosporine results in increased phosphorylation of MAPK1 protein]; Pertussis Toxin inhibits the reaction [TAS2R105 protein affects the reaction [Cycloheximide results in increased phosphorylation of MAPK1 protein]] |
CTD |
PMID:12472888 PMID:15087236 PMID:16696851 PMID:22155090 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Asbestos, Crocidolite results in decreased phosphorylation of MAPK14 protein] |
CTD |
PMID:17507666 |
|
NCBI chr20:5,933,290...5,995,137
Ensembl chr20:5,933,303...5,995,137
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases phosphorylation multiple interactions |
ISO EXP |
Cycloheximide results in increased phosphorylation of MAPK3 protein Cycloheximide inhibits the reaction [KNG1 protein results in increased phosphorylation of MAPK3 protein]; Cycloheximide promotes the reaction [sodium arsenite promotes the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK3 protein]] Cycloheximide inhibits the reaction [Cyclosporine results in increased phosphorylation of MAPK3 protein]; Pertussis Toxin inhibits the reaction [TAS2R105 protein affects the reaction [Cycloheximide results in increased phosphorylation of MAPK3 protein]] |
CTD |
PMID:12472888 PMID:15087236 PMID:16696851 PMID:22155090 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Mapk7 |
mitogen-activated protein kinase 7 |
multiple interactions increases expression |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of MAPK7 mRNA; Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of MAPK7 mRNA] Cycloheximide results in increased expression of MAPK7 mRNA |
CTD |
PMID:11007951 PMID:19684285 |
|
NCBI chr10:47,768,592...47,775,130
Ensembl chr10:47,766,680...47,775,055
|
|
G |
Mapkapk3 |
MAPK activated protein kinase 3 |
affects response to substance |
ISO |
MAPKAPK3 gene SNP affects the susceptibility to Cycloheximide |
CTD |
PMID:25622337 |
|
NCBI chr 8:116,012,126...116,046,012
Ensembl chr 8:116,012,121...116,045,954
|
|
G |
Mbp |
myelin basic protein |
affects expression |
EXP |
Cycloheximide affects the expression of MBP mRNA |
CTD |
PMID:22954530 |
|
NCBI chr18:79,326,738...79,437,310
Ensembl chr18:79,326,738...79,437,310
|
|
G |
Mcl1 |
MCL1 apoptosis regulator, BCL2 family member |
multiple interactions decreases expression |
ISO |
[Cycloheximide co-treated with MCL1] results in increased susceptibility to ABT-737; [resveratrol co-treated with clofarabine co-treated with Cycloheximide] results in decreased expression of MCL1 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide results in decreased expression of MCL1 protein]; Cycloheximide inhibits the reaction [EIF4E protein modified form inhibits the reaction [sodium arsenite results in decreased expression of MCL1 protein]] |
CTD |
PMID:14982947 PMID:21880625 PMID:24924397 PMID:25408576 PMID:25923732 |
|
NCBI chr 2:197,786,212...197,788,992
|
|
G |
Mdk |
midkine |
multiple interactions |
ISO |
Cycloheximide promotes the reaction [Tetrachlorodibenzodioxin results in decreased expression of MDK mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 3:80,841,003...80,843,895
Ensembl chr 3:80,841,005...80,842,916
|
|
G |
Mir21 |
microRNA 21 |
multiple interactions increases expression |
ISO |
Cycloheximide inhibits the reaction [Dihydrotestosterone results in increased expression of MIR21 mRNA]; Cycloheximide inhibits the reaction [Estradiol results in decreased expression of MIR21 mRNA]; Cycloheximide inhibits the reaction [fludioxonil results in increased expression of MIR21 mRNA]; Cycloheximide inhibits the reaction [N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide results in increased expression of MIR21 mRNA] Cycloheximide results in increased expression of MIR21 mRNA |
CTD |
PMID:19264808 PMID:23052036 |
|
NCBI chr10:73,902,210...73,902,301
Ensembl chr10:73,902,210...73,902,301
|
|
G |
Mitf |
melanocyte inducing transcription factor |
multiple interactions |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[Cycloheximide co-treated with 4-(1-phenylethyl)-1,3-benzenediol] results in increased degradation of MITF protein]; [Cycloheximide co-treated with 4-(1-phenylethyl)-1,3-benzenediol] results in increased degradation of MITF protein |
CTD |
PMID:30849679 |
|
NCBI chr 4:130,172,484...130,425,496
Ensembl chr 4:130,172,727...130,425,532
|
|
G |
Mmp1 |
matrix metallopeptidase 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of MMP1 protein]; Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of MMP1 mRNA] |
CTD |
PMID:15075337 PMID:19136476 |
|
NCBI chr 8:5,703,206...5,723,593
Ensembl chr 8:5,703,206...5,723,591
|
|
G |
Mmp13 |
matrix metallopeptidase 13 |
increases expression multiple interactions |
ISO |
Cycloheximide results in increased expression of MMP13 mRNA Cycloheximide inhibits the reaction [Tretinoin results in increased expression of MMP13 mRNA] [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of MMP13 mRNA |
CTD |
PMID:16350840 PMID:19684285 |
|
NCBI chr 8:5,522,739...5,533,018
Ensembl chr 8:5,522,739...5,533,018
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Vehicle Emissions results in increased expression of MMP2 mRNA] |
CTD |
PMID:26621329 |
|
NCBI chr19:15,542,771...15,570,589
Ensembl chr19:15,542,765...15,570,611
|
|
G |
Mnx1 |
motor neuron and pancreas homeobox 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of MNX1 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 4:2,376,350...2,381,308
Ensembl chr 4:2,376,958...2,381,271
|
|
G |
Mpg |
N-methylpurine-DNA glycosylase |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of MPG mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr10:15,661,768...15,667,995
Ensembl chr10:15,661,608...15,668,022
|
|
G |
Mrps7 |
mitochondrial ribosomal protein S7 |
decreases expression multiple interactions |
ISO |
Cycloheximide results in decreased expression of MRPS7 mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] affects the expression of MRPS7 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr10:104,155,805...104,158,840
Ensembl chr10:104,155,805...104,158,839
|
|
G |
Msh3 |
mutS homolog 3 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of MSH3 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 2:21,790,048...21,931,791
Ensembl chr 2:21,790,044...21,931,720
|
|
G |
Msr1 |
macrophage scavenger receptor 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MSR1 mRNA] |
CTD |
PMID:9614211 |
|
NCBI chr16:56,817,714...56,900,025
Ensembl chr16:56,813,791...56,900,052
|
|
G |
Mt1 |
metallothionein 1 |
multiple interactions increases expression |
ISO |
2-tert-butylhydroquinone promotes the reaction [Cycloheximide results in increased expression of MT1 mRNA]; Cycloheximide promotes the reaction [2-tert-butylhydroquinone results in increased expression of MT1 mRNA]; Cycloheximide promotes the reaction [arsenic trichloride results in increased expression of MT1 mRNA]; MTF1 protein affects the reaction [Cycloheximide promotes the reaction [arsenic trichloride results in increased expression of MT1 mRNA]]; MTF1 protein affects the reaction [Cycloheximide results in increased expression of MT1 mRNA] |
CTD |
PMID:14998373 PMID:19276070 |
|
NCBI chr19:11,301,991...11,303,007
Ensembl chr17:78,793,336...78,793,724
|
|
G |
Mtch2 |
mitochondrial carrier 2 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of MTCH2 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 3:79,678,141...79,695,356
Ensembl chr 3:79,678,201...79,694,006
|
|
G |
Mtf1 |
metal-regulatory transcription factor 1 |
multiple interactions |
ISO |
MTF1 protein affects the reaction [Cycloheximide promotes the reaction [arsenic trichloride results in increased expression of MT1 mRNA]]; MTF1 protein affects the reaction [Cycloheximide results in increased expression of MT1 mRNA] |
CTD |
PMID:19276070 |
|
NCBI chr 5:142,797,340...142,843,896
Ensembl chr 5:142,797,366...142,842,122
|
|
G |
Mtmr7 |
myotubularin related protein 7 |
increases expression multiple interactions |
ISO |
Cycloheximide results in increased expression of MTMR7 mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of MTMR7 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr16:54,765,214...54,856,255
Ensembl chr16:54,765,325...54,856,225
|
|
G |
Mxd1 |
max dimerization protein 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of MXD1 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 4:118,451,752...118,472,150
Ensembl chr 4:118,449,882...118,472,179
|
|
G |
Mxd3 |
Max dimerization protein 3 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of MXD3 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr17:9,830,326...9,834,052
Ensembl chr17:9,830,332...9,839,452
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions |
ISO EXP |
Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of MYC protein] Cycloheximide inhibits the reaction [MLN7243 results in increased sumoylation of MYC protein] Cycloheximide promotes the reaction [Cadmium results in increased expression of MYC mRNA] |
CTD |
PMID:1696944 PMID:23593480 PMID:31285264 |
|
NCBI chr 7:102,586,313...102,591,240
Ensembl chr 7:102,586,313...102,591,240
|
|
G |
Mylk |
myosin light chain kinase |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [TNF protein results in increased expression of MYLK protein] |
CTD |
PMID:15701621 |
|
NCBI chr11:69,013,060...69,260,039
Ensembl chr11:69,013,050...69,223,158
|
|
G |
Myo1d |
myosin ID |
affects response to substance |
ISO |
MYO1D gene SNP affects the susceptibility to Cycloheximide |
CTD |
PMID:25622337 |
|
NCBI chr10:67,866,939...68,142,864
Ensembl chr10:67,866,940...68,142,864
|
|
G |
Nbr1 |
NBR1, autophagy cargo receptor |
increases expression multiple interactions |
ISO |
Cycloheximide results in increased expression of NBR1 mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of NBR1 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr10:89,455,202...89,483,791
Ensembl chr10:89,459,650...89,484,080
|
|
G |
Ndrg1 |
N-myc downstream regulated 1 |
multiple interactions decreases expression |
ISO |
Chloroquine inhibits the reaction [Cycloheximide results in decreased expression of NDRG1 protein] |
CTD |
PMID:28906492 |
|
NCBI chr 7:107,734,326...107,775,701
Ensembl chr 7:107,734,323...107,775,714
|
|
G |
Nedd4 |
NEDD4 E3 ubiquitin protein ligase |
decreases expression multiple interactions |
ISO |
Cycloheximide results in decreased expression of NEDD4 protein Melatonin promotes the reaction [Cycloheximide results in decreased expression of NEDD4 protein] |
CTD |
PMID:31325559 |
|
NCBI chr 8:79,323,408...79,408,842
Ensembl chr 8:79,323,408...79,408,833
|
|
G |
Nefh |
neurofilament heavy |
decreases expression |
EXP |
Cycloheximide results in decreased expression of NEFH mRNA |
CTD |
PMID:19146868 |
|
NCBI chr14:85,181,572...85,191,557
Ensembl chr14:85,181,572...85,191,557
|
|
G |
Nefl |
neurofilament light |
decreases expression |
EXP |
Cycloheximide results in decreased expression of NEFL mRNA |
CTD |
PMID:19146868 |
|
NCBI chr15:44,799,378...44,803,251
Ensembl chr15:44,799,334...44,804,574
|
|
G |
Nek2 |
NIMA-related kinase 2 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of NEK2 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr13:110,511,546...110,524,750
Ensembl chr13:110,511,668...110,522,769
|
|
G |
Nfe2l2 |
nuclear factor, erythroid 2-like 2 |
multiple interactions decreases expression |
ISO |
[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Cycloheximide] results in increased expression of NFE2L2 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide inhibits the reaction [Particulate Matter analog results in increased expression of NFE2L2 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide inhibits the reaction [Vehicle Emissions analog results in increased expression of NFE2L2 protein]]; Cycloheximide inhibits the reaction [Cadmium Chloride results in increased expression of and results in increased activity of NFE2L2 protein]; Cycloheximide inhibits the reaction [Particulate Matter analog results in increased expression of NFE2L2 protein]; Cycloheximide inhibits the reaction [Vehicle Emissions analog results in increased expression of NFE2L2 protein]; exenatide inhibits the reaction [Cycloheximide results in decreased expression of NFE2L2 protein] [SB 203580 co-treated with Cycloheximide] inhibits the reaction [Quercetin results in decreased expression of NFE2L2 protein]; Cycloheximide inhibits the reaction [[SB 203580 co-treated with Quercetin] results in increased expression of NFE2L2 protein]; Cycloheximide inhibits the reaction [Quercetin results in increased expression of NFE2L2 protein]; Cycloheximide inhibits the reaction [SB 203580 affects the reaction [Quercetin affects the localization of NFE2L2 protein]]; Cycloheximide inhibits the reaction [sulforafan results in increased expression of NFE2L2 protein] |
CTD |
PMID:12441344 PMID:14510636 PMID:15322212 PMID:22019695 PMID:22197970 PMID:25896339 PMID:27939242 |
|
NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
affects localization multiple interactions increases expression |
ISO |
Cycloheximide affects the localization of NFKB1 protein Cycloheximide results in decreased expression of [NFKB1 protein binds to RELA protein]; TNF protein promotes the reaction [Cycloheximide results in increased expression of NFKB1 mRNA]; Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of NFKB1 mRNA]] |
CTD |
PMID:16637064 PMID:21146893 |
|
NCBI chr 2:240,773,520...240,890,053
Ensembl chr 2:240,773,456...240,866,689
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions decreases expression increases degradation |
ISO |
Cycloheximide inhibits the reaction [Morphine results in increased expression of NFKBIA mRNA]; Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of NFKBIA mRNA]; Cycloheximide promotes the reaction [Tetradecanoylphorbol Acetate results in decreased expression of NFKBIA protein]; Cycloheximide promotes the reaction [Tetradecanoylphorbol Acetate results in increased degradation of NFKBIA protein]; NFKBIA protein affects the reaction [Cycloheximide promotes the reaction [N(1),N(11)-diethylnorspermine results in increased expression of SAT1 mRNA]]; Tetradecanoylphorbol Acetate promotes the reaction [Cycloheximide results in decreased expression of NFKBIA protein]; Tetradecanoylphorbol Acetate promotes the reaction [Cycloheximide results in increased degradation of NFKBIA protein] |
CTD |
PMID:11007951 PMID:15330761 PMID:16637064 PMID:21692457 PMID:22258905 |
|
NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
|
|
G |
Ngf |
nerve growth factor |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [NGF protein results in increased expression of FOS protein]; Cycloheximide inhibits the reaction [NGF protein results in increased expression of SOD2 protein] |
CTD |
PMID:20495008 |
|
NCBI chr 2:204,886,158...204,939,523
Ensembl chr 2:204,886,202...204,940,453
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [tetrachlorobenzoquinone results in increased expression of NLRP3 protein] |
CTD |
PMID:26901245 |
|
NCBI chr10:45,884,324...45,918,290
Ensembl chr10:45,893,018...45,918,254
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Cyclosporine results in increased expression of NOS2 protein]; Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of NOS2 mRNA] |
CTD |
PMID:10760090 PMID:11007951 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Nos3 |
nitric oxide synthase 3 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of NOS3 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 4:7,321,908...7,342,404
Ensembl chr 4:7,320,668...7,342,410
|
|
G |
Npy1r |
neuropeptide Y receptor Y1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of NPY1R mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr16:24,779,480...24,789,131
Ensembl chr16:24,779,477...24,788,740
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
decreases expression multiple interactions |
ISO EXP |
Cycloheximide results in decreased expression of NQO1 mRNA Cycloheximide inhibits the reaction [notoginsenoside R1 results in increased expression of NQO1 protein] benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide inhibits the reaction [Lead results in increased expression of NQO1 mRNA]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide inhibits the reaction [Mercury results in increased expression of NQO1 mRNA]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of NQO1 mRNA]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide promotes the reaction [Copper results in decreased expression of NQO1 mRNA]]; Cycloheximide inhibits the reaction [2-tert-butylhydroquinone results in increased expression of NQO1 mRNA]; Cycloheximide inhibits the reaction [arsenite results in increased expression of NQO1 mRNA]; Cycloheximide inhibits the reaction [Cadmium results in increased expression of NQO1 mRNA]; Cycloheximide inhibits the reaction [Lead results in increased expression of NQO1 mRNA]; Cycloheximide inhibits the reaction [Mercury results in increased expression of NQO1 mRNA]; Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of NQO1 mRNA]; Cycloheximide promotes the reaction [Chromium results in increased expression of NQO1 mRNA]; Cycloheximide promotes the reaction [Copper results in decreased expression of NQO1 mRNA] |
CTD |
PMID:14510636 PMID:16243960 PMID:18474416 PMID:24437944 |
|
NCBI chr19:38,422,210...38,437,103
Ensembl chr19:38,422,164...38,437,180
|
|
G |
Nr0b1 |
nuclear receptor subfamily 0, group B, member 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Bucladesine results in decreased expression of NR0B1 mRNA]; Cycloheximide inhibits the reaction [Tetradecanoylphorbol Acetate results in decreased expression of NR0B1 mRNA] |
CTD |
PMID:18787026 |
|
NCBI chr X:54,734,385...54,738,513
Ensembl chr X:54,734,385...54,738,513
|
|
G |
Nr1h3 |
nuclear receptor subfamily 1, group H, member 3 |
multiple interactions increases expression |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of NR1H3 mRNA Cycloheximide results in increased expression of NR1H3 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 3:80,004,130...80,014,197
Ensembl chr 3:80,004,130...80,012,750
|
|
G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
multiple interactions |
ISO EXP |
Cycloheximide inhibits the reaction [Dexamethasone affects the localization of NR3C1 protein]; Cycloheximide inhibits the reaction [Dexamethasone binds to NR3C1 protein]; Cycloheximide inhibits the reaction [Dexamethasone results in increased degradation of NR3C1 protein] Cycloheximide promotes the reaction [tubacin results in decreased expression of and results in increased degradation of NR3C1 mRNA] |
CTD |
PMID:21569845 PMID:31778773 |
|
NCBI chr18:31,728,373...32,704,022
Ensembl chr18:31,728,373...31,749,647
|
|
G |
Nr4a1 |
nuclear receptor subfamily 4, group A, member 1 |
multiple interactions |
EXP |
Cycloheximide promotes the reaction [LHB protein results in increased expression of NR4A1 mRNA] |
CTD |
PMID:11416027 |
|
NCBI chr 7:142,899,358...142,920,216
Ensembl chr 7:142,905,758...142,920,216
|
|
G |
Nucks1 |
nuclear casein kinase and cyclin-dependent kinase substrate 1 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of NUCKS1 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr13:48,679,726...48,709,663
Ensembl chr13:48,679,774...48,705,575
|
|
G |
Odc1 |
ornithine decarboxylase 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Paraquat results in increased activity of ODC1 protein] |
CTD |
PMID:7662713 |
|
NCBI chr 6:42,852,529...42,859,142
Ensembl chr 6:42,852,683...42,859,927
|
|
G |
Opa1 |
OPA1, mitochondrial dynamin like GTPase |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [15-deoxyprostaglandin J2 results in increased expression of OPA1 protein alternative form] |
CTD |
PMID:20678484 |
|
NCBI chr11:74,717,600...74,793,902
Ensembl chr11:74,720,254...74,793,803
|
|
G |
Oprk1 |
opioid receptor, kappa 1 |
multiple interactions increases expression |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of OPRK1 mRNA Cycloheximide results in increased expression of OPRK1 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 5:13,742,655...13,760,460
Ensembl chr 5:13,744,658...13,760,305
|
|
G |
Oprm1 |
opioid receptor, mu 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Dronabinol results in increased expression of OPRM1 mRNA] |
CTD |
PMID:16434616 |
|
NCBI chr 1:43,454,803...43,704,948
Ensembl chr 1:43,454,803...43,704,948
|
|
G |
Orm1 |
orosomucoid 1 |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [Dexamethasone results in increased expression of ORM1 mRNA] |
CTD |
PMID:20599767 |
|
NCBI chr 5:79,179,668...79,182,820
Ensembl chr 5:79,179,417...79,182,820
|
|
G |
Pa2g4 |
proliferation-associated 2G4 |
multiple interactions |
ISO |
PA2G4 protein promotes the reaction [Cycloheximide results in decreased expression of ERBB2 protein] |
CTD |
PMID:20379846 |
|
NCBI chr 7:2,979,587...2,987,055
Ensembl chr 7:2,979,588...2,987,055
|
|
G |
Pappa1 |
pappalysin 1 |
increases expression multiple interactions |
ISO |
Cycloheximide results in increased expression of PAPPA mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of PAPPA mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 5:80,919,932...81,153,904
Ensembl chr 5:80,920,568...81,150,940
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions increases cleavage |
ISO EXP |
[Cycloheximide co-treated with TNF protein] results in increased cleavage of PARP1 protein; [Cycloheximide co-treated with TNFSF10 protein] results in increased cleavage of PARP1 protein; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of PARP1 protein]; ITPK1 mutant form promotes the reaction [[Cycloheximide co-treated with TNF protein] results in increased cleavage of PARP1 protein] Cycloheximide inhibits the reaction [ammonium acetate results in increased expression of PARP1 protein] Cycloheximide results in increased cleavage of PARP1 protein |
CTD |
PMID:12925536 PMID:15147502 PMID:16051428 PMID:18222423 |
|
NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
|
|
G |
Pax3 |
paired box 3 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of PAX3 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 9:84,004,004...84,101,226
Ensembl chr 9:84,005,183...84,101,172
|
|
G |
Pcgf1 |
polycomb group ring finger 1 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of PCGF1 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 4:113,911,129...113,913,718
Ensembl chr 4:113,910,685...113,913,687
|
|
G |
Pck1 |
phosphoenolpyruvate carboxykinase 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Dexamethasone results in decreased expression of PCK1 mRNA] |
CTD |
PMID:9518257 |
|
NCBI chr 3:171,213,936...171,219,885
Ensembl chr 3:171,213,936...171,219,871
|
|
G |
Pcna |
proliferating cell nuclear antigen |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Vitamin K 3 results in decreased expression of PCNA protein] |
CTD |
PMID:21533478 |
|
NCBI chr 3:124,880,698...124,884,570
Ensembl chr 3:124,880,698...124,884,570
|
|
G |
Pdcd2 |
programmed cell death 2 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PDCD2 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 1:57,512,968...57,518,458
Ensembl chr 1:57,512,968...57,518,458
|
|
G |
Pi4ka |
phosphatidylinositol 4-kinase alpha |
multiple interactions |
ISO |
Cycloheximide promotes the reaction [Tetrachlorodibenzodioxin results in decreased expression of PI4KA mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr11:87,858,323...87,975,549
Ensembl chr11:87,858,453...87,973,422
|
|
G |
Pigh |
phosphatidylinositol glycan anchor biosynthesis, class H |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of PIGH mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 6:102,258,621...102,272,826
Ensembl chr 6:102,263,337...102,272,777
|
|
G |
Pigk |
phosphatidylinositol glycan anchor biosynthesis, class K |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of PIGK mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 2:257,911,099...257,997,735
Ensembl chr 2:257,911,126...257,997,733
|
|
G |
Pik3c3 |
phosphatidylinositol 3-kinase, catalytic subunit type 3 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of PIK3C3 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr18:22,964,121...23,047,896
Ensembl chr18:22,964,210...23,047,895
|
|
G |
Pik3cg |
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit gamma |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of PIK3CG mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 6:51,465,696...51,501,234
Ensembl chr 6:51,465,908...51,498,337
|
|
G |
Pilrb |
paired immunoglobin-like type 2 receptor beta |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of PILRB mRNA |
CTD |
PMID:19684285 |
|
NCBI chr12:20,140,405...20,142,844
Ensembl chr12:20,140,765...20,142,069
|
|
G |
Pla2g1b |
phospholipase A2 group IB |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PLA2G1B mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr12:46,879,346...46,890,234
Ensembl chr12:46,879,343...46,889,082
|
|
G |
Pla2g4a |
phospholipase A2 group IVA |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Dexamethasone inhibits the reaction [Zymosan results in increased activity of PLA2G4A protein]] |
CTD |
PMID:10874129 |
|
NCBI chr13:67,062,252...67,206,688
Ensembl chr13:66,988,937...67,206,693
|
|
G |
Plat |
plasminogen activator, tissue type |
multiple interactions |
EXP |
Cycloheximide promotes the reaction [Isoproterenol results in increased expression of PLAT mRNA] |
CTD |
PMID:2477232 |
|
NCBI chr16:74,098,263...74,122,897
Ensembl chr16:74,098,260...74,122,889
|
|
G |
Plaur |
plasminogen activator, urokinase receptor |
multiple interactions increases expression |
ISO |
[Cycloheximide co-treated with IFNA2 protein] results in increased expression of PLAUR mRNA; [Cycloheximide co-treated with IFNG protein] results in increased expression of PLAUR mRNA Cycloheximide results in increased expression of PLAUR mRNA |
CTD |
PMID:12070711 |
|
NCBI chr 1:81,328,171...81,344,954
Ensembl chr 1:81,328,183...81,344,708
|
|
G |
Pld3 |
phospholipase D family, member 3 |
increases expression multiple interactions |
ISO |
Cycloheximide results in increased expression of PLD3 mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of PLD3 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 1:84,339,269...84,361,686
Ensembl chr 1:84,339,261...84,353,725
|
|
G |
Pln |
phospholamban |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of PLN mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr20:34,633,157...34,642,904
Ensembl chr20:34,633,157...34,642,904
|
|
G |
Plp1 |
proteolipid protein 1 |
multiple interactions increases expression |
EXP |
Cycloheximide promotes the reaction [Tretinoin results in increased expression of PLP1 mRNA] Cycloheximide results in increased expression of PLP1 mRNA |
CTD |
PMID:19450544 |
|
NCBI chr X:107,494,326...107,511,355
Ensembl chr X:107,496,072...107,511,348
|
|
G |
Pmaip1 |
phorbol-12-myristate-13-acetate-induced protein 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Fenretinide results in increased expression of PMAIP1 protein]; Cycloheximide inhibits the reaction [Thapsigargin results in increased expression of PMAIP1 protein] |
CTD |
PMID:17216584 |
|
NCBI chr18:62,159,128...62,179,635
Ensembl chr18:62,174,670...62,181,102
|
|
G |
Pml |
PML nuclear body scaffold |
decreases degradation multiple interactions |
ISO |
Cycloheximide results in decreased degradation of PML protein modified form Cycloheximide inhibits the reaction [arsenic trioxide results in increased degradation of PML protein] |
CTD |
PMID:20943951 PMID:26049103 |
|
NCBI chr 8:63,002,515...63,034,310
Ensembl chr 8:63,004,870...63,034,226
|
|
G |
Pnpla2 |
patatin-like phospholipase domain containing 2 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PNPLA2 protein] |
CTD |
PMID:18643838 |
|
NCBI chr 1:214,434,638...214,439,720
Ensembl chr 1:214,434,626...214,439,720
|
|
G |
Pnpla6 |
patatin-like phospholipase domain containing 6 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of PNPLA6 protein]; Cycloheximide inhibits the reaction [Bucladesine results in increased activity of PNPLA6 protein]; Cycloheximide inhibits the reaction [Colforsin results in increased activity of PNPLA6 protein] |
CTD |
PMID:20380879 |
|
NCBI chr12:2,068,749...2,098,139
Ensembl chr12:2,069,959...2,097,904
|
|
G |
Pomc |
proopiomelanocortin |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [POMC protein modified form results in increased chemical synthesis of Adrenal Cortex Hormones] |
CTD |
PMID:2993719 |
|
NCBI chr 6:28,382,937...28,388,771
Ensembl chr 6:28,382,962...28,388,967
|
|
G |
Por |
cytochrome p450 oxidoreductase |
multiple interactions decreases expression |
ISO |
POR protein mutant form promotes the reaction [Cycloheximide results in decreased expression of POR protein] |
CTD |
PMID:27496950 |
|
NCBI chr12:23,998,411...24,017,063
Ensembl chr12:23,998,411...24,046,814
|
|
G |
Pou5f1 |
POU class 5 homeobox 1 |
multiple interactions |
ISO |
Cycloheximide promotes the reaction [Cobalt results in increased expression of POU5F1 protein]; Cycloheximide promotes the reaction [nickel chloride results in increased expression of POU5F1 protein] |
CTD |
PMID:24497960 |
|
NCBI chr20:3,747,231...3,751,994
Ensembl chr20:3,747,221...3,751,994
|
|
G |
Ppan |
peter pan homolog |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of PPAN mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 8:21,905,865...21,909,845
Ensembl chr 8:21,905,865...21,909,842
|
|
G |
Ppp1r15a |
protein phosphatase 1, regulatory subunit 15A |
decreases expression multiple interactions |
ISO |
Cycloheximide results in decreased expression of PPP1R15A protein arsenite inhibits the reaction [Cycloheximide results in decreased expression of PPP1R15A protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide results in decreased expression of PPP1R15A protein]; Cycloheximide affects the reaction [arsenite results in increased expression of PPP1R15A protein]; Cycloheximide inhibits the reaction [Thapsigargin results in increased expression of PPP1R15A protein] |
CTD |
PMID:29109149 |
|
NCBI chr 1:101,511,899...101,515,043
Ensembl chr 1:101,511,901...101,514,974
|
|
G |
Ppp3cb |
protein phosphatase 3 catalytic subunit beta |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of PPP3CB mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr15:4,209,702...4,236,895
Ensembl chr15:4,209,703...4,236,895
|
|
G |
Ppp4r3b |
protein phosphatase 4, regulatory subunit 3B |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of PPP4R3B mRNA |
CTD |
PMID:19684285 |
|
NCBI chr14:113,570,150...113,618,138
Ensembl chr14:113,570,150...113,618,138
|
|
G |
Prdx4 |
peroxiredoxin 4 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PRDX4 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr X:43,495,453...43,512,994
Ensembl chr X:43,497,763...43,512,991
|
|
G |
Prkcb |
protein kinase C, beta |
decreases expression multiple interactions |
ISO |
Cycloheximide results in decreased expression of PRKCB mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of PRKCB mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 1:192,233,569...192,575,339
Ensembl chr 1:192,233,910...192,574,831
|
|
G |
Prkcd |
protein kinase C, delta |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [Buthionine Sulfoximine results in increased expression of PRKCD protein]; Cycloheximide inhibits the reaction [diethyl maleate results in increased expression of PRKCD protein] |
CTD |
PMID:11118818 |
|
NCBI chr16:6,655,131...6,675,746
Ensembl chr16:6,655,120...6,675,746
|
|
G |
Prkce |
protein kinase C, epsilon |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [Buthionine Sulfoximine results in increased expression of PRKCE protein]; Cycloheximide inhibits the reaction [diethyl maleate results in increased expression of PRKCE protein] |
CTD |
PMID:11118818 |
|
NCBI chr 6:9,483,400...9,973,396
Ensembl chr 6:9,790,422...9,973,396
|
|
G |
Prkcz |
protein kinase C, zeta |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PRKCZ mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 5:172,658,071...172,769,492
Ensembl chr 5:172,658,748...172,769,421
|
|
G |
Psen1 |
presenilin 1 |
multiple interactions |
ISO |
[PSEN1 protein affects the susceptibility to Ammonium Chloride] affects the reaction [Cycloheximide results in decreased expression of RBPJ protein]; [PSEN1 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] affects the reaction [Cycloheximide results in decreased expression of RBPJ protein]; [PSEN1 protein affects the susceptibility to SB 203580] affects the reaction [Cycloheximide results in decreased expression of RBPJ protein]; Cycloheximide affects the reaction [PSEN1 protein affects the expression of RBPJ protein] |
CTD |
PMID:22302987 |
|
NCBI chr 6:107,169,514...107,221,000
Ensembl chr 6:107,169,528...107,216,798
|
|
G |
Psen2 |
presenilin 2 |
multiple interactions |
ISO |
Cycloheximide affects the reaction [PSEN2 protein affects the expression of RBPJ protein]; PSEN2 protein affects the reaction [Cycloheximide results in decreased expression of RBPJ protein] |
CTD |
PMID:22302987 |
|
NCBI chr13:98,513,600...98,539,347
Ensembl chr13:98,513,570...98,530,724
|
|
G |
Psmd1 |
proteasome 26S subunit, non-ATPase 1 |
multiple interactions |
ISO |
PSMD1 protein affects the reaction [Cycloheximide results in increased degradation of MAF1 protein] |
CTD |
PMID:31645432 |
|
NCBI chr 9:93,080,618...93,155,033
Ensembl chr 9:93,080,615...93,155,027
|
|
G |
Psme3 |
proteasome activator subunit 3 |
multiple interactions |
ISO |
PSME3 protein affects the reaction [Cycloheximide results in decreased expression of CDKN1A protein] |
CTD |
PMID:31645432 |
|
NCBI chr10:89,236,256...89,244,041
Ensembl chr10:89,236,256...89,244,041
|
|
G |
Pten |
phosphatase and tensin homolog |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Lovastatin results in increased expression of PTEN protein]; Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PTEN protein] |
CTD |
PMID:16425225 |
|
NCBI chr 1:251,421,814...251,487,634
Ensembl chr 1:251,421,596...251,487,832
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions increases expression |
ISO EXP |
Cycloheximide inhibits the reaction [Dinoprostone promotes the reaction [IL1B protein results in increased expression of PTGS2 protein]]; Cycloheximide inhibits the reaction [IL1B protein results in increased expression of PTGS2 protein]; Cycloheximide inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased activity of PTGS2 protein]; Cycloheximide inhibits the reaction [Tretinoin results in increased expression of PTGS2 protein] Cycloheximide results in increased expression of PTGS2 mRNA benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide inhibits the reaction [cadmium sulfate results in increased expression of PTGS2 protein]]; Cycloheximide inhibits the reaction [cadmium sulfate results in increased expression of PTGS2 protein]; Cycloheximide inhibits the reaction [KNG1 protein results in increased phosphorylation of PTGS2 protein]; Cycloheximide promotes the reaction [IL1B protein results in increased expression of PTGS2 mRNA] |
CTD |
PMID:7575673 PMID:11112151 PMID:11286988 PMID:16696851 PMID:16894348 PMID:22767315 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Ptn |
pleiotrophin |
increases expression multiple interactions |
ISO |
Cycloheximide results in increased expression of PTN mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of PTN mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 4:64,239,156...64,330,996
Ensembl chr 4:64,239,158...64,330,996
|
|
G |
Ptp4a1 |
protein tyrosine phosphatase 4A1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Medroxyprogesterone Acetate inhibits the reaction [Estradiol results in increased expression of PTP4A1 mRNA]]; Cycloheximide promotes the reaction [Estradiol results in increased expression of PTP4A1 mRNA] |
CTD |
PMID:19146866 |
|
NCBI chr 9:37,223,363...37,254,222
Ensembl chr 9:37,223,729...37,231,291
|
|
G |
Ptp4a3 |
protein tyrosine phosphatase 4A3 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of PTP4A3 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 7:114,969,699...115,002,902
Ensembl chr 7:114,997,103...115,002,902
|
|
G |
Ptpn5 |
protein tyrosine phosphatase, non-receptor type 5 |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [Isoproterenol results in increased expression of PTPN5 protein] |
CTD |
PMID:17623046 |
|
NCBI chr 1:103,197,918...103,258,309
Ensembl chr 1:103,197,915...103,256,823
|
|
G |
Rabepk |
Rab9 effector protein with kelch motifs |
affects response to substance |
ISO |
RABEPK gene SNP affects the susceptibility to Cycloheximide |
CTD |
PMID:25622337 |
|
NCBI chr 3:13,845,352...13,865,843
Ensembl chr 3:13,845,361...13,865,843
|
|
G |
Rapgef1 |
Rap guanine nucleotide exchange factor 1 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of RAPGEF1 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 3:8,189,594...8,307,077
Ensembl chr 3:8,192,575...8,304,976
|
|
G |
Rarb |
retinoic acid receptor, beta |
multiple interactions increases expression |
EXP |
Cycloheximide promotes the reaction [Tretinoin results in increased expression of RARB mRNA] Cycloheximide results in increased expression of RARB mRNA |
CTD |
PMID:19450544 |
|
NCBI chr15:9,915,223...10,262,599
Ensembl chr15:10,120,206...10,262,599
|
|
G |
Rarres2 |
retinoic acid receptor responder 2 |
increases expression multiple interactions |
ISO |
Cycloheximide results in increased expression of RARRES2 mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of RARRES2 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 4:78,205,809...78,208,956
Ensembl chr 4:78,205,812...78,208,767
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
multiple interactions |
ISO |
RB1 protein affects the reaction [palbociclib promotes the reaction [Cycloheximide results in decreased expression of RBL1 protein]] |
CTD |
PMID:20100483 |
|
NCBI chr15:55,081,582...55,209,060
Ensembl chr15:55,083,140...55,209,342
|
|
G |
Rbl1 |
RB transcriptional corepressor like 1 |
multiple interactions decreases expression |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of RBL1 mRNA]; palbociclib promotes the reaction [Cycloheximide results in decreased expression of RBL1 protein]; RB1 protein affects the reaction [palbociclib promotes the reaction [Cycloheximide results in decreased expression of RBL1 protein]] |
CTD |
PMID:11007951 PMID:20100483 |
|
NCBI chr 3:153,263,692...153,321,351
Ensembl chr 3:153,263,692...153,321,352
|
|
G |
Rbpj |
recombination signal binding protein for immunoglobulin kappa J region |
decreases expression multiple interactions |
ISO |
Cycloheximide results in decreased expression of RBPJ protein [PSEN1 protein affects the susceptibility to Ammonium Chloride] affects the reaction [Cycloheximide results in decreased expression of RBPJ protein]; [PSEN1 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] affects the reaction [Cycloheximide results in decreased expression of RBPJ protein]; [PSEN1 protein affects the susceptibility to SB 203580] affects the reaction [Cycloheximide results in decreased expression of RBPJ protein]; Cycloheximide affects the reaction [PSEN1 protein affects the expression of RBPJ protein]; Cycloheximide affects the reaction [PSEN2 protein affects the expression of RBPJ protein]; Cycloheximide inhibits the reaction [Ammonium Chloride results in increased expression of RBPJ protein]; Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of RBPJ protein]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Cycloheximide results in decreased expression of RBPJ protein]; PSEN2 protein affects the reaction [Cycloheximide results in decreased expression of RBPJ protein] |
CTD |
PMID:22302987 |
|
NCBI chr14:59,657,738...59,865,427
Ensembl chr14:59,658,935...59,735,450
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions affects localization |
ISO |
[Cycloheximide co-treated with N(1),N(11)-diethylnorspermine] promotes the reaction [RELA protein binds to SAT1 promoter]; Cycloheximide promotes the reaction [RELA protein binds to SAT1 promoter]; Cycloheximide results in decreased expression of [NFKB1 protein binds to RELA protein] Cycloheximide affects the localization of RELA protein |
CTD |
PMID:16637064 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
Ren |
renin |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Dobutamine results in increased secretion of REN protein]; Cycloheximide inhibits the reaction [Terbutaline results in increased secretion of REN protein] |
CTD |
PMID:9203624 |
|
NCBI chr13:50,502,724...50,513,953
Ensembl chr13:50,502,724...50,514,151
|
|
G |
Ret |
ret proto-oncogene |
decreases expression |
EXP |
Cycloheximide results in decreased expression of RET protein |
CTD |
PMID:17555550 |
|
NCBI chr 4:150,202,170...150,249,196
Ensembl chr 4:150,202,058...150,244,372
|
|
G |
RGD1304694 |
similar to CG9646-PA |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of KIAA0930 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 7:125,853,573...125,893,168
Ensembl chr 7:125,857,046...125,893,168
|
|
G |
Rgn |
regucalcin |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Zinc Sulfate results in increased expression of RGN mRNA] |
CTD |
PMID:18327666 |
|
NCBI chr X:1,833,484...1,848,904
Ensembl chr X:1,833,492...1,848,904
|
|
G |
Rhob |
ras homolog family member B |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [cytotoxic necrotizing factor type 1 results in increased expression of RHOB protein] |
CTD |
PMID:23732113 |
|
NCBI chr 6:33,689,127...33,691,301
Ensembl chr 6:33,689,127...33,691,301
|
|
G |
Rictor |
RPTOR independent companion of MTOR, complex 2 |
multiple interactions |
ISO |
Cycloheximide promotes the reaction [FBXW7 protein binds to and results in decreased expression of RICTOR protein] Cycloheximide inhibits the reaction [Thapsigargin affects the localization of RICTOR mRNA] |
CTD |
PMID:25897075 PMID:29576526 |
|
NCBI chr 2:56,013,898...56,105,818
Ensembl chr 2:56,052,643...56,101,803
|
|
G |
Rnf4 |
ring finger protein 4 |
decreases expression multiple interactions |
ISO |
Cycloheximide results in decreased expression of RNF4 protein Cycloheximide inhibits the reaction [MLN7243 affects the localization of RNF4 protein] |
CTD |
PMID:20943951 PMID:31285264 |
|
NCBI chr14:81,658,400...81,679,756
Ensembl chr14:81,660,354...81,679,082
|
|
G |
Rps27l |
ribosomal protein S27-like |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of RPS27L mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 8:72,741,155...72,746,090
Ensembl chr 8:72,741,155...72,746,090
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [EGF protein results in increased phosphorylation of RPS6KB1 protein]] |
CTD |
PMID:22689575 |
|
NCBI chr10:73,824,200...73,865,503
Ensembl chr10:73,824,202...73,865,364
|
|
G |
Rrm2 |
ribonucleotide reductase regulatory subunit M2 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Progesterone results in increased expression of RRM2 mRNA] |
CTD |
PMID:22403396 |
|
NCBI chr 6:43,884,627...43,890,818
Ensembl chr 6:43,884,678...43,889,515
|
|
G |
Runx2 |
RUNX family transcription factor 2 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Cryptoxanthins results in increased expression of RUNX2 mRNA]; Cycloheximide inhibits the reaction [Zinc Sulfate results in increased expression of RUNX2 mRNA] |
CTD |
PMID:15962303 PMID:18327666 |
|
NCBI chr 9:18,564,743...18,773,092
Ensembl chr 9:18,564,927...18,773,092
|
|
G |
S100a4 |
S100 calcium-binding protein A4 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of S100A4 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 2:189,997,278...189,999,587
Ensembl chr 2:189,997,129...189,999,604
|
|
G |
S100b |
S100 calcium binding protein B |
decreases expression |
EXP |
Cycloheximide results in decreased expression of S100B mRNA |
CTD |
PMID:19146868 |
|
NCBI chr20:13,130,633...13,142,856
Ensembl chr20:13,130,636...13,142,856
|
|
G |
Sat1 |
spermidine/spermine N1-acetyl transferase 1 |
multiple interactions |
ISO |
[Cycloheximide co-treated with N(1),N(11)-diethylnorspermine] promotes the reaction [RELA protein binds to SAT1 promoter]; Cycloheximide promotes the reaction [N(1),N(11)-diethylnorspermine results in increased expression of SAT1 mRNA]; Cycloheximide promotes the reaction [RELA protein binds to SAT1 promoter]; NFKBIA protein affects the reaction [Cycloheximide promotes the reaction [N(1),N(11)-diethylnorspermine results in increased expression of SAT1 mRNA]] |
CTD |
PMID:16637064 |
|
NCBI chr X:43,626,480...43,629,767
Ensembl chr X:43,625,169...43,629,765
|
|
G |
Scd |
stearoyl-CoA desaturase |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Clofibrate results in increased expression of SCD1 mRNA] |
CTD |
PMID:8790349 |
|
NCBI chr 1:264,159,966...264,173,061
Ensembl chr 1:264,160,129...264,172,729
|
|
G |
Sec11c |
SEC11 homolog C, signal peptidase complex subunit |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] affects the expression of SEC11C mRNA |
CTD |
PMID:19684285 |
|
NCBI chr18:61,490,051...61,506,393
Ensembl chr18:61,490,031...61,506,508
|
|
G |
Serpinb9 |
serpin family B member 9 |
multiple interactions |
ISO |
Cycloheximide promotes the reaction [moxestrol results in increased expression of SERPINB9 mRNA] |
CTD |
PMID:10681578 |
|
NCBI chr17:32,648,846...32,673,047
Ensembl chr17:32,650,441...32,661,865
|
|
G |
Serpine1 |
serpin family E member 1 |
multiple interactions |
ISO EXP |
Cycloheximide promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of SERPINE1 mRNA] Cycloheximide inhibits the reaction [TGFB1 protein results in increased expression of SERPINE1 mRNA]; Cycloheximide promotes the reaction [FGF2 protein results in increased expression of SERPINE1 mRNA] Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of SERPINE1 mRNA] |
CTD |
PMID:9798919 PMID:11007951 PMID:12111005 |
|
NCBI chr12:22,641,104...22,651,482
Ensembl chr12:22,641,104...22,651,482
|
|
G |
Serpine2 |
serpin family E member 2 |
increases expression multiple interactions |
ISO |
Cycloheximide results in increased expression of SERPINE2 mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of SERPINE2 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 9:85,560,852...85,629,410
Ensembl chr 9:85,560,863...85,626,094
|
|
G |
Sertad2 |
SERTA domain containing 2 |
increases expression multiple interactions |
ISO |
Cycloheximide results in increased expression of SERTAD2 mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of SERTAD2 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr14:104,786,649...104,890,022
Ensembl chr14:104,821,215...104,886,197
|
|
G |
Sesn2 |
sestrin 2 |
multiple interactions decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide results in decreased expression of SESN2 protein]; Cycloheximide inhibits the reaction [Lipopolysaccharides results in increased expression of SESN2 protein] |
CTD |
PMID:25637945 |
|
NCBI chr 5:150,684,891...150,703,846
Ensembl chr 5:150,684,133...150,704,117
|
|
G |
Sgk1 |
serum/glucocorticoid regulated kinase 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Cadmium Chloride results in increased expression of SGK1 protein] |
CTD |
PMID:25128767 |
|
NCBI chr 1:24,185,451...24,302,309
Ensembl chr 1:24,185,435...24,302,298
|
|
G |
Sirpa |
signal-regulatory protein alpha |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of SIRPA mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 3:122,113,735...122,152,478
Ensembl chr 3:122,114,108...122,152,477
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions decreases expression |
ISO |
Cycloheximide promotes the reaction [antimony trichloride results in decreased expression of SIRT1 protein]; pyrazolanthrone inhibits the reaction [Silicon Dioxide promotes the reaction [Cycloheximide results in decreased expression of SIRT1 protein]]; Silicon Dioxide promotes the reaction [Cycloheximide results in decreased expression of SIRT1 protein] |
CTD |
PMID:30055241 PMID:31082419 |
|
NCBI chr20:26,831,971...26,851,587
Ensembl chr20:26,833,357...26,852,199
|
|
G |
Sla |
src-like adaptor |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tretinoin results in increased expression of SLA mRNA] |
CTD |
PMID:9020066 |
|
NCBI chr 7:107,585,055...107,604,950
Ensembl chr 7:107,584,118...107,634,335
|
|
G |
Slc16a1 |
solute carrier family 16 member 1 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of SLC16A1 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 2:207,108,552...207,129,352
Ensembl chr 2:207,108,552...207,128,554
|
|
G |
Slc1a1 |
solute carrier family 1 member 1 |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [Tretinoin results in increased expression of SLC1A1 mRNA] |
CTD |
PMID:19450544 |
|
NCBI chr 1:246,955,017...247,035,159
Ensembl chr 1:246,954,980...247,037,056
|
|
G |
Slc22a4 |
solute carrier family 22 member 4 |
increases expression multiple interactions |
ISO |
Cycloheximide results in increased expression of SLC22A4 mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of SLC22A4 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr10:39,334,972...39,373,508
|
|
G |
Slc25a27 |
solute carrier family 25, member 27 |
increases expression |
ISO |
Cycloheximide results in increased expression of SLC25A27 mRNA |
CTD |
PMID:20385226 |
|
NCBI chr 9:19,880,468...19,907,506
Ensembl chr 9:19,880,473...19,907,458
|
|
G |
Slc2a1 |
solute carrier family 2 member 1 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of SLC2A1 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 5:138,154,677...138,182,897
Ensembl chr 5:138,154,673...138,182,897
|
|
G |
Slc2a5 |
solute carrier family 2 member 5 |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [Fructose promotes the reaction [SLC2A5 protein results in increased uptake of Fructose]] |
CTD |
PMID:11123204 |
|
NCBI chr 5:167,142,182...167,174,203
Ensembl chr 5:167,141,875...167,174,310
|
|
G |
Slc39a4 |
solute carrier family 39 member 4 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Zinc deficiency results in increased expression of SLC39A4 mRNA]; Cycloheximide inhibits the reaction [Zinc results in decreased expression of SLC39A4 mRNA] |
CTD |
PMID:18020946 |
|
NCBI chr 7:117,675,718...117,682,586
Ensembl chr 7:117,675,720...117,680,004
|
|
G |
Slc3a2 |
solute carrier family 3 member 2 |
increases expression |
ISO |
Cycloheximide results in increased expression of SLC3A2 mRNA |
CTD |
PMID:26621329 |
|
NCBI chr 1:224,906,566...224,921,029
Ensembl chr 1:224,906,554...224,921,092
|
|
G |
Slc5a5 |
solute carrier family 5 member 5 |
increases expression |
ISO |
Cycloheximide results in increased expression of SLC5A5 mRNA |
CTD |
PMID:17164311 |
|
NCBI chr16:20,297,414...20,307,401
Ensembl chr16:20,297,414...20,307,400
|
|
G |
Slc7a5 |
solute carrier family 7 member 5 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of SLC7A5 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr19:54,693,959...54,722,563
Ensembl chr19:54,693,959...54,722,563
|
|
G |
Smn1 |
survival of motor neuron 1, telomeric |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Paraquat results in increased expression of SMN1 mRNA alternative form] |
CTD |
PMID:17064354 |
|
NCBI chr 2:30,360,101...30,371,147
Ensembl chr 2:30,360,100...30,371,147
|
|
G |
Snw1 |
SNW domain containing 1 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of SNW1 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 6:111,483,698...111,507,782
Ensembl chr 6:111,483,703...111,507,782
|
|
G |
Socs1 |
suppressor of cytokine signaling 1 |
multiple interactions increases expression |
ISO |
[afimoxifene co-treated with Cycloheximide] results in increased expression of SOCS1 mRNA Cycloheximide results in increased expression of SOCS1 mRNA |
CTD |
PMID:16849584 PMID:23237828 |
|
NCBI chr10:4,956,795...4,958,472
Ensembl chr10:4,957,326...4,958,461
|
|
G |
Socs2 |
suppressor of cytokine signaling 2 |
multiple interactions increases expression |
ISO |
Cycloheximide promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of SOCS2 mRNA] Cycloheximide results in increased expression of SOCS2 mRNA |
CTD |
PMID:15371557 PMID:23237828 |
|
NCBI chr 7:36,495,496...36,500,878
Ensembl chr 7:36,495,480...36,499,784
|
|
G |
Socs3 |
suppressor of cytokine signaling 3 |
increases expression multiple interactions |
ISO |
Cycloheximide results in increased expression of SOCS3 mRNA Dactinomycin inhibits the reaction [Cycloheximide results in increased expression of SOCS3 mRNA]; U 0126 inhibits the reaction [Cycloheximide results in increased expression of SOCS3 mRNA] |
CTD |
PMID:23237828 |
|
NCBI chr10:106,973,863...106,976,969
Ensembl chr10:106,975,178...106,976,040
|
|
G |
Socs4 |
suppressor of cytokine signaling 4 |
increases expression |
ISO |
Cycloheximide results in increased expression of SOCS4 mRNA |
CTD |
PMID:23237828 |
|
NCBI chr15:24,056,383...24,070,868
Ensembl chr15:24,056,383...24,070,857
|
|
G |
Socs5 |
suppressor of cytokine signaling 5 |
increases expression |
ISO |
Cycloheximide results in increased expression of SOCS5 mRNA |
CTD |
PMID:23237828 |
|
NCBI chr 6:10,671,311...10,705,610
Ensembl chr 6:10,674,371...10,704,977
|
|
G |
Socs6 |
suppressor of cytokine signaling 6 |
increases expression |
ISO |
Cycloheximide results in increased expression of SOCS6 mRNA |
CTD |
PMID:23237828 |
|
NCBI chr18:85,962,729...85,981,125
Ensembl chr18:85,962,729...85,980,833
|
|
G |
Socs7 |
suppressor of cytokine signaling 7 |
increases expression |
ISO |
Cycloheximide results in increased expression of SOCS7 mRNA |
CTD |
PMID:23237828 |
|
NCBI chr10:85,301,797...85,337,971
Ensembl chr10:85,301,875...85,330,397
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions increases expression |
ISO |
Cycloheximide inhibits the reaction [NGF protein results in increased expression of SOD2 protein]; Cycloheximide inhibits the reaction [polysaccharide-K results in increased expression of SOD2] Cycloheximide results in increased expression of SOD2 mRNA Cycloheximide promotes the reaction [Paclitaxel results in increased expression of SOD2 mRNA]; Cycloheximide promotes the reaction [Tetradecanoylphorbol Acetate results in increased expression of SOD2 mRNA]; Cycloheximide promotes the reaction [TNF protein results in increased expression of SOD2 mRNA]; Cycloheximide promotes the reaction [Vinblastine results in increased expression of SOD2 mRNA]; Cycloheximide promotes the reaction [Vincristine results in increased expression of SOD2 mRNA]; Tetradecanoylphorbol Acetate promotes the reaction [Cycloheximide results in increased expression of SOD2 mRNA] |
CTD |
PMID:8037686 PMID:9852137 PMID:11154046 PMID:15330761 PMID:20495008 |
|
NCBI chr 1:47,914,757...47,921,587
Ensembl chr 1:47,914,759...47,921,587
|
|
G |
Sort1 |
sortilin 1 |
multiple interactions increases degradation |
EXP ISO |
SORT1 mutant form inhibits the reaction [Pentanoic Acids results in decreased susceptibility to [TNF protein co-treated with Cycloheximide]]; SORT1 mutant form inhibits the reaction [sodium arsenite results in decreased susceptibility to [TNF protein co-treated with Cycloheximide]] Cycloheximide results in increased degradation of SORT1 protein mutant form Cycloheximide promotes the reaction [Palmitic Acid results in increased degradation of SORT1 protein]; Docosahexaenoic Acids inhibits the reaction [Cycloheximide promotes the reaction [Palmitic Acid results in increased degradation of SORT1 protein]] |
CTD |
PMID:22555848 PMID:24986865 PMID:25805502 |
|
NCBI chr 2:211,078,092...211,156,312
Ensembl chr 2:211,078,334...211,156,312
|
|
G |
Sos1 |
SOS Ras/Rac guanine nucleotide exchange factor 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of SOS1 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 6:3,105,443...3,182,977
Ensembl chr 6:3,104,861...3,182,996
|
|
G |
Sptan1 |
spectrin, alpha, non-erythrocytic 1 |
multiple interactions |
ISO |
[TNF co-treated with Cycloheximide] results in increased cleavage of SPTAN1 protein; VASP mutant form promotes the reaction [[TNF co-treated with Cycloheximide] results in increased cleavage of SPTAN1 protein] |
CTD |
PMID:18182247 |
|
NCBI chr 3:8,534,437...8,599,259
Ensembl chr 3:8,534,440...8,599,260
|
|
G |
Src |
SRC proto-oncogene, non-receptor tyrosine kinase |
increases localization |
EXP |
Cycloheximide results in increased localization of SRC protein |
CTD |
PMID:10401681 |
|
NCBI chr 3:153,547,807...153,595,643
Ensembl chr 3:153,580,861...153,595,642
|
|
G |
Srr |
serine racemase |
multiple interactions |
ISO EXP |
Cycloheximide inhibits the reaction [methyllycaconitine results in increased expression of SRR protein] |
CTD |
PMID:24012499 |
|
NCBI chr10:61,756,138...61,772,327
Ensembl chr10:61,756,138...61,772,293
|
|
G |
Ssbp1 |
single stranded DNA binding protein 1 |
increases expression multiple interactions |
ISO |
Cycloheximide results in increased expression of SSBP1 mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of SSBP1 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 4:68,634,844...68,645,112
Ensembl chr 4:68,634,929...68,645,172
|
|
G |
St18 |
ST18 C2H2C-type zinc finger transcription factor |
increases expression |
ISO |
Cycloheximide results in increased expression of ST18 mRNA |
CTD |
PMID:23236509 |
|
NCBI chr 5:12,437,617...12,787,223
Ensembl chr 5:12,437,525...12,563,429
|
|
G |
St8sia1 |
ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 1 |
multiple interactions increases expression |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of ST8SIA1 mRNA Cycloheximide results in increased expression of ST8SIA1 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 4:177,065,266...177,195,942
Ensembl chr 4:177,065,168...177,196,180
|
|
G |
Stk3 |
serine/threonine kinase 3 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of STK3 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 7:73,617,926...73,883,896
Ensembl chr 7:73,618,644...73,883,812
|
|
G |
Stx2 |
syntaxin 2 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of STX2 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr12:31,324,203...31,360,249
Ensembl chr12:31,335,372...31,360,254
|
|
G |
Sult1a1 |
sulfotransferase family 1A member 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Gallic Acid results in increased expression of SULT1A1 mRNA] |
CTD |
PMID:16308312 |
|
NCBI chr 1:198,100,586...198,104,106
Ensembl chr 1:198,100,586...198,104,109
|
|
G |
Sult2b1 |
sulfotransferase family 2B member 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of SULT2B1 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 1:101,712,254...101,774,683
Ensembl chr 1:101,710,959...101,773,508
|
|
G |
Supt4h1 |
SPT4 homolog, DSIF elongation factor subunit |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of SUPT4H1 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr10:75,032,365...75,038,547
Ensembl chr10:75,032,365...75,038,547
|
|
G |
Synpo |
synaptopodin |
multiple interactions increases expression |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of SYNPO mRNA Cycloheximide results in increased expression of SYNPO mRNA |
CTD |
PMID:19684285 |
|
NCBI chr18:55,863,081...55,921,412
Ensembl chr18:55,865,467...55,916,220
|
|
G |
Tac1 |
tachykinin, precursor 1 |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [KNG1 protein results in increased secretion of TAC1 protein] |
CTD |
PMID:16696851 |
|
NCBI chr 4:33,638,853...33,646,819
Ensembl chr 4:33,638,709...33,646,819
|
|
G |
Tacc1 |
transforming, acidic coiled-coil containing protein 1 |
multiple interactions increases expression |
ISO |
[Cycloheximide co-treated with Estradiol] results in decreased expression of TACC1 mRNA Cycloheximide results in increased expression of TACC1 mRNA |
CTD |
PMID:15072547 |
|
NCBI chr16:71,596,970...71,681,126
Ensembl chr16:71,629,525...71,681,126
|
|
G |
Tardbp |
TAR DNA binding protein |
multiple interactions decreases expression |
ISO |
Cycloheximide results in decreased expression of and results in decreased stability of TARDBP protein mutant form; epoxomicin inhibits the reaction [Cycloheximide results in decreased expression of and results in decreased stability of TARDBP protein mutant form]; epoxomicin inhibits the reaction [Cycloheximide results in decreased expression of TARDBP protein] |
CTD |
PMID:24477737 |
|
NCBI chr 5:165,432,089...165,442,232
Ensembl chr 5:165,432,095...165,442,048
|
|
G |
Tas2r106 |
taste receptor, type 2, member 106 |
multiple interactions |
ISO |
TAS2R105 protein affects the reaction [Cycloheximide results in increased phosphorylation of MAPK1 protein]; TAS2R105 protein affects the reaction [Cycloheximide results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:15087236 |
|
NCBI chr 4:165,786,745...165,787,668
Ensembl chr 4:165,786,745...165,787,668
|
|
G |
Testin |
testin gene |
multiple interactions decreases secretion decreases expression |
EXP |
Cycloheximide inhibits the reaction [lonidamine results in increased expression of TESTIN mRNA]; Cycloheximide inhibits the reaction [lonidamine results in increased secretion of TESTIN protein] Cycloheximide results in decreased secretion of TESTIN protein Cycloheximide results in decreased expression of TESTIN mRNA |
CTD |
PMID:11090432 |
|
NCBI chr17:4,194,796...4,225,376
Ensembl chr17:4,212,890...4,225,376
|
|
G |
Tff1 |
trefoil factor 1 |
multiple interactions increases expression |
ISO |
[Cycloheximide co-treated with Estradiol] results in increased expression of TFF1 mRNA; Cycloheximide inhibits the reaction [bisphenol A results in increased expression of TFF1 mRNA] Cycloheximide results in increased expression of TFF1 mRNA |
CTD |
PMID:15072547 PMID:20875696 |
|
NCBI chr20:9,892,124...9,895,984
Ensembl chr20:9,892,124...9,895,984
|
|
G |
Tgfa |
transforming growth factor alpha |
increases expression |
ISO |
Cycloheximide results in increased expression of TGFA mRNA |
CTD |
PMID:15228094 |
|
NCBI chr 4:117,961,877...118,045,923
Ensembl chr 4:117,962,319...118,046,344
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions decreases activity |
EXP ISO |
Cycloheximide inhibits the reaction [TGFB1 protein results in increased expression of BAX protein]; Cycloheximide inhibits the reaction [TGFB1 protein results in increased expression of SERPINE1 mRNA]; Cycloheximide inhibits the reaction [TGFB1 protein results in increased expression of TP53 protein] Cycloheximide results in decreased activity of TGFB1 protein Cycloheximide inhibits the reaction [TGFB1 protein inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]]; Cycloheximide inhibits the reaction [TGFB1 protein inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1B1 mRNA]]; Cycloheximide inhibits the reaction [TGFB1 protein results in decreased expression of AHR mRNA]; Cycloheximide inhibits the reaction [TGFB1 protein results in increased expression of ITGB6 mRNA] |
CTD |
PMID:9145908 PMID:9790906 PMID:9798919 PMID:21303922 PMID:31652400 |
|
NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
|
|
G |
Tgfbr2 |
transforming growth factor, beta receptor 2 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [tolfenamic acid results in decreased expression of TGFBR2 protein] |
CTD |
PMID:31381904 |
|
NCBI chr 8:124,310,288...124,399,345
Ensembl chr 8:124,312,754...124,399,494
|
|
G |
Thbd |
thrombomodulin |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of THBD mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 3:142,748,673...142,752,325
Ensembl chr 3:142,748,674...142,752,325
|
|
G |
Thbs1 |
thrombospondin 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Testosterone results in decreased expression of THBS1 mRNA] |
CTD |
PMID:16723184 |
|
NCBI chr 3:109,862,120...109,873,466
Ensembl chr 3:109,862,117...109,873,466
|
|
G |
Thy1 |
Thy-1 cell surface antigen |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of THY1 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 8:48,382,121...48,387,271
Ensembl chr 8:48,382,121...48,386,935
|
|
G |
Tia1 |
TIA1 cytotoxic granule-associated RNA binding protein |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [sodium arsenite affects the localization of TIA1 protein]; TIA1 mutant form inhibits the reaction [Pentanoic Acids results in decreased susceptibility to [TNF protein co-treated with Cycloheximide]]; TIA1 mutant form inhibits the reaction [sodium arsenite results in decreased susceptibility to [TNF protein co-treated with Cycloheximide]] |
CTD |
PMID:19171178 PMID:22555848 |
|
NCBI chr 4:118,207,845...118,238,246
Ensembl chr 4:118,207,862...118,235,218
|
|
G |
Timm17a |
translocase of inner mitochondrial membrane 17A |
multiple interactions decreases expression |
ISO |
Cycloheximide results in decreased expression of and results in increased degradation of TIMM17A protein; YME1L1 mutant form inhibits the reaction [Cycloheximide results in increased degradation of TIMM17A protein] Cycloheximide results in decreased expression of TIMM17A protein |
CTD |
PMID:24315374 |
|
NCBI chr13:52,124,641...52,136,127
Ensembl chr13:52,124,635...52,136,127
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
decreases response to substance |
EXP |
TIMP1 protein results in decreased susceptibility to Cycloheximide |
CTD |
PMID:15860571 |
|
NCBI chr X:1,364,771...1,369,451
Ensembl chr X:1,364,786...1,369,384
|
|
G |
Tiparp |
TCDD-inducible poly(ADP-ribose) polymerase |
multiple interactions increases expression |
ISO |
AHR protein promotes the reaction [Cycloheximide results in increased expression of TIPARP mRNA]; Cycloheximide promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of TIPARP mRNA] |
CTD |
PMID:12147270 |
|
NCBI chr 2:157,316,293...157,342,979
Ensembl chr 2:157,316,266...157,341,469
|
|
G |
Tjp1 |
tight junction protein 1 |
multiple interactions decreases expression |
ISO |
Cycloheximide inhibits the reaction [IFNG protein results in increased expression of TJP1 protein] Cycloheximide results in decreased expression of TJP1 protein |
CTD |
PMID:16087364 |
|
NCBI chr 1:126,146,489...126,515,359
Ensembl chr 1:126,146,489...126,227,469
|
|
G |
Tm7sf3 |
transmembrane 7 superfamily member 3 |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of TM7SF3 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 4:180,913,703...180,951,564
Ensembl chr 4:180,913,706...180,951,564
|
|
G |
Tmem263 |
transmembrane protein 263 |
increases expression multiple interactions |
ISO |
Cycloheximide results in increased expression of TMEM263 mRNA [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of TMEM263 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 7:24,647,083...24,668,381
Ensembl chr 7:24,647,083...24,668,250
|
|
G |
Tnf |
tumor necrosis factor |
increases response to substance multiple interactions |
ISO EXP |
TNF protein results in increased susceptibility to Cycloheximide [Cycloheximide co-treated with TNF protein] results in increased cleavage of PARP1 protein; [Cycloheximide co-treated with TNF] results in increased activity of CASP9 protein; [Cycloheximide co-treated with TNF] results in increased cleavage of and results in increased activity of CASP3 protein; [Cycloheximide co-treated with TNF] results in increased cleavage of and results in increased activity of CASP8 protein; [Cycloheximide co-treated with TNF] results in increased cleavage of BID protein; [TNF protein co-treated with Cycloheximide] results in increased expression of TNFAIP3 mRNA; [TNF protein co-treated with Cycloheximide] results in increased secretion of CXCL8 protein; Cycloheximide inhibits the reaction [CXCL8 protein affects the secretion of TNF protein]; Cycloheximide inhibits the reaction [Morphine inhibits the reaction [TNF protein results in increased expression of CNR1 mRNA]]; Cycloheximide inhibits the reaction [Morphine inhibits the reaction [TNF protein results in increased expression of CXCL8 mRNA]]; Cycloheximide inhibits the reaction [SM 164 results in increased expression of TNF mRNA]; Cycloheximide inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of TNF protein]; Cycloheximide inhibits the reaction [TNF protein results in increased expression of CCL2 protein]; Cycloheximide inhibits the reaction [TNF protein results in increased expression of CCL5 protein]; Cycloheximide inhibits the reaction [TNF protein results in increased expression of CXCL10 protein]; Cycloheximide inhibits the reaction [TNF protein results in increased expression of MYLK protein]; Cycloheximide inhibits the reaction [tofacitinib inhibits the reaction [TNF protein results in increased expression of CCL2 protein]]; Cycloheximide inhibits the reaction [tofacitinib inhibits the reaction [TNF protein results in increased expression of CCL5 protein]]; Cycloheximide inhibits the reaction [tofacitinib inhibits the reaction [TNF protein results in increased expression of CXCL10 protein]]; Cycloheximide inhibits the reaction [Zinc deficiency promotes the reaction [Tetradecanoylphorbol Acetate results in increased expression of TNF protein]]; Cycloheximide promotes the reaction [TNF protein results in increased expression of SOD2 mRNA]; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased activity of CASP9 protein]; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of and results in increased activity of CASP3 protein]; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of and results in increased activity of CASP8 protein]; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of BID protein]; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of PARP1 protein]; ITPK1 mutant form promotes the reaction [[Cycloheximide co-treated with TNF protein] results in increased cleavage of BID protein]; ITPK1 mutant form promotes the reaction [[Cycloheximide co-treated with TNF protein] results in increased cleavage of PARP1 protein]; ITPK1 mutant form results in increased susceptibility to [Cycloheximide co-treated with TNF protein]; TNF protein promotes the reaction [Cycloheximide results in increased expression of CCL2 mRNA]; TNF protein promotes the reaction [Cycloheximide results in increased expression of CCL5 mRNA]; TNF protein promotes the reaction [Cycloheximide results in increased expression of CXCL8 mRNA]; TNF protein promotes the reaction [Cycloheximide results in increased expression of IL6 mRNA]; TNF protein promotes the reaction [Cycloheximide results in increased expression of NFKB1 mRNA]; TNF protein promotes the reaction [Cycloheximide results in increased secretion of IL6 protein]; Ursodeoxycholic Acid analog inhibits the reaction [[TNF protein co-treated with Cycloheximide] results in increased secretion of CXCL8 protein]; Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of CCL2 mRNA]]; Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of CCL5 mRNA]]; Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of CXCL8 mRNA]]; Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of IL6 mRNA]]; Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of NFKB1 mRNA]]; Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased secretion of IL6 protein]]; Ursodeoxycholic Acid analog promotes the reaction [[TNF protein co-treated with Cycloheximide] results in increased expression of TNFAIP3 mRNA] Cycloheximide inhibits the reaction [TNF protein results in decreased export of Potassium]; Pentanoic Acids results in decreased susceptibility to [TNF protein co-treated with Cycloheximide]; sodium arsenite results in decreased susceptibility to [TNF protein co-treated with Cycloheximide]; SORT1 mutant form inhibits the reaction [Pentanoic Acids results in decreased susceptibility to [TNF protein co-treated with Cycloheximide]]; SORT1 mutant form inhibits the reaction [sodium arsenite results in decreased susceptibility to [TNF protein co-treated with Cycloheximide]]; TIA1 mutant form inhibits the reaction [Pentanoic Acids results in decreased susceptibility to [TNF protein co-treated with Cycloheximide]]; TIA1 mutant form inhibits the reaction [sodium arsenite results in decreased susceptibility to [TNF protein co-treated with Cycloheximide]] [TNF co-treated with Cycloheximide] results in increased cleavage of SPTAN1 protein; Cycloheximide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of TNF protein]; Cycloheximide inhibits the reaction [Poly I-C results in increased secretion of TNF protein]; Cycloheximide promotes the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; VASP mutant form promotes the reaction [[TNF co-treated with Cycloheximide] results in increased cleavage of SPTAN1 protein] |
CTD |
PMID:8037686 PMID:8071060 PMID:12185005 PMID:12812920 PMID:12925536 PMID:15701621 PMID:16077199 PMID:17337591 PMID:18182247 PMID:21146893 PMID:22121136 PMID:22241084 PMID:22258905 PMID:22319556 PMID:22555848 PMID:24068670 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Tnfaip3 |
TNF alpha induced protein 3 |
multiple interactions |
ISO |
[TNF protein co-treated with Cycloheximide] results in increased expression of TNFAIP3 mRNA; Ursodeoxycholic Acid analog promotes the reaction [[TNF protein co-treated with Cycloheximide] results in increased expression of TNFAIP3 mRNA] |
CTD |
PMID:21146893 |
|
NCBI chr 1:14,401,103...14,416,369
Ensembl chr 1:14,402,913...14,412,807
|
|
G |
Tnfrsf10b |
TNF receptor superfamily member 10b |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Docetaxel results in increased expression of TNFRSF10A protein]; Cycloheximide inhibits the reaction [Paclitaxel results in increased expression of TNFRSF10A protein] |
CTD |
PMID:11212279 |
|
NCBI chr15:51,433,853...51,464,215
|
|
G |
Tnfrsf11b |
TNF receptor superfamily member 11B |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in decreased expression of TNFRSF11B mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 7:93,798,580...93,826,586
Ensembl chr 7:93,798,545...93,826,665
|
|
G |
Tnfrsf26 |
tumor necrosis factor receptor superfamily, member 26 |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [tetrachlorobenzoquinone results in increased expression of TNFRSF10B mRNA] |
CTD |
PMID:27484784 |
|
NCBI chr 1:216,808,642...216,829,361
Ensembl chr 1:216,808,632...216,828,651
|
|
G |
Tnfrsf8 |
TNF receptor superfamily member 8 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of TNFRSF8 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 5:163,186,349...163,231,578
Ensembl chr 5:163,186,349...163,231,578
|
|
G |
Tnfsf10 |
TNF superfamily member 10 |
multiple interactions |
ISO |
[Cycloheximide co-treated with TNFSF10 protein] results in increased activity of CASP3 protein; [Cycloheximide co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP8 protein; [Cycloheximide co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP9 protein; [Cycloheximide co-treated with TNFSF10 protein] results in increased cleavage of PARP1 protein; [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide promotes the reaction [sodium arsenite results in increased expression of and results in increased localization of TNFRSF10B protein]] results in increased susceptibility to [TNFSF10 protein co-treated with Cycloheximide]; BCL2 protein inhibits the reaction [[Cycloheximide co-treated with TNFSF10 protein] results in increased activity of CASP3 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[Cycloheximide co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP3 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[Cycloheximide co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP8 protein]; Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of TNFSF10 mRNA] |
CTD |
PMID:11007951 PMID:18222423 PMID:22343715 |
|
NCBI chr 2:113,008,008...113,026,899
Ensembl chr 2:113,007,549...113,026,899
|
|
G |
Tnfsf11 |
TNF superfamily member 11 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of TNFSF11 mRNA] Cycloheximide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein co-treated with Cryptoxanthins] promotes the reaction [Zinc Sulfate results in increased expression of CASP3 mRNA]]; Cycloheximide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein co-treated with Zinc Sulfate] promotes the reaction [Cryptoxanthins results in increased expression of CASP3 mRNA]]; Cycloheximide inhibits the reaction [Genistein promotes the reaction [[Zinc Sulfate co-treated with CSF1 protein co-treated with TNFSF11 protein] results in increased expression of CASP3 mRNA]]; Cycloheximide inhibits the reaction [Zinc Sulfate results in increased expression of TNFSF11 mRNA] |
CTD |
PMID:11007951 PMID:17295206 PMID:18327666 PMID:18636177 |
|
NCBI chr15:60,482,527...60,512,704
Ensembl chr15:60,482,527...60,512,704
|
|
G |
Tnnc1 |
troponin C1, slow skeletal and cardiac type |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of TNNC1 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr16:7,292,207...7,295,238
Ensembl chr16:7,292,096...7,295,465
|
|
G |
Tp53 |
tumor protein p53 |
increases response to substance increases degradation decreases expression multiple interactions |
ISO EXP |
TP53 mutant form results in increased susceptibility to Cycloheximide Cycloheximide results in increased degradation of TP53 protein Cycloheximide results in decreased expression of TP53 protein Cycloheximide inhibits the reaction [Cyclosporine results in increased expression of TRP53 protein] Cycloheximide inhibits the reaction [TGFB1 protein results in increased expression of TP53 protein] Cycloheximide inhibits the reaction [Fluorouracil results in increased expression of TP53 protein]; Cycloheximide promotes the reaction [Chlorpyrifos results in decreased expression of TP53 protein]; leptomycin B inhibits the reaction [Cycloheximide results in increased degradation of TP53 protein] |
CTD |
PMID:9790906 PMID:10760090 PMID:15016801 PMID:20943951 PMID:21875941 PMID:27993609 PMID:31645432 |
|
NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
|
|
G |
Tp53i11 |
tumor protein p53 inducible protein 11 |
multiple interactions decreases expression |
ISO |
Cycloheximide inhibits the reaction [arsenic trioxide results in increased expression of TP53I11 mRNA] Cycloheximide results in decreased expression of TP53I11 mRNA |
CTD |
PMID:19333544 |
|
NCBI chr 3:82,081,838...82,097,064
Ensembl chr 3:82,081,906...82,097,056
|
|
G |
Tp63 |
tumor protein p63 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [trichostatin A results in increased expression of TP63 protein alternative form] |
CTD |
PMID:20043870 |
|
NCBI chr11:78,234,853...78,456,559
Ensembl chr11:78,234,800...78,456,501
|
|
G |
Tubgcp3 |
tubulin, gamma complex associated protein 3 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of TUBGCP3 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr16:82,184,362...82,245,041
Ensembl chr16:82,184,387...82,245,041
|
|
G |
Txnrd1 |
thioredoxin reductase 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Acrolein results in increased expression of TXNRD1 mRNA]; Cycloheximide inhibits the reaction [sulforafan results in increased expression of TXNRD1 mRNA] |
CTD |
PMID:12663510 PMID:15652504 |
|
NCBI chr 7:26,946,124...26,984,400
Ensembl chr 7:26,946,125...26,984,400
|
|
G |
Tymp |
thymidine phosphorylase |
decreases expression multiple interactions |
ISO |
Cycloheximide results in decreased expression of TYMP protein salinomycin inhibits the reaction [Cycloheximide results in decreased expression of TYMP protein]; tanespimycin inhibits the reaction [salinomycin inhibits the reaction [Cycloheximide results in decreased expression of TYMP protein]] |
CTD |
PMID:30796972 |
|
NCBI chr 7:130,342,481...130,347,845
Ensembl chr 7:130,342,483...130,347,587
|
|
G |
Tyms |
thymidylate synthetase |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [trichostatin A results in decreased expression of TYMS mRNA] |
CTD |
PMID:17172411 |
|
NCBI chr 9:121,918,875...121,931,564
Ensembl chr 9:121,918,947...121,931,564
|
|
G |
Tyr |
tyrosinase |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Quercetin results in increased activity of TYR protein] [resorcinol co-treated with Cycloheximide] results in increased expression of TYR protein; SB 203580 inhibits the reaction [[resorcinol co-treated with Cycloheximide] results in increased expression of TYR protein] |
CTD |
PMID:14717847 PMID:29621941 |
|
NCBI chr 1:151,012,598...151,106,802
Ensembl chr 1:151,012,598...151,106,802
|
|
G |
Uchl1 |
ubiquitin C-terminal hydrolase L1 |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [Mevinphos results in increased expression of UCHL1 protein] |
CTD |
PMID:15545831 |
|
NCBI chr14:43,133,224...43,143,942
Ensembl chr14:43,133,218...43,143,973
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
multiple interactions decreases expression |
ISO |
[Cycloheximide co-treated with Estradiol] results in decreased expression of UGT1A1 mRNA Cycloheximide results in decreased expression of UGT1A1 mRNA |
CTD |
PMID:15072547 |
|
NCBI chr 9:95,295,701...95,302,822
Ensembl chr 9:95,161,157...95,302,822
|
|
G |
Ugt1a6 |
UDP glucuronosyltransferase family 1 member A6 |
multiple interactions |
EXP |
Cycloheximide inhibits the reaction [Paraquat results in increased expression of UGT1A6 mRNA] |
CTD |
PMID:22846377 |
|
NCBI chr 9:95,241,609...95,302,822
Ensembl chr 9:95,161,157...95,302,822
|
|
G |
Ulk1 |
unc-51 like autophagy activating kinase 1 |
decreases expression multiple interactions |
ISO |
Cycloheximide results in decreased expression of ULK1 protein Antimycin A inhibits the reaction [Cycloheximide results in decreased expression of ULK1 protein]; Cycloheximide inhibits the reaction [Antimycin A results in increased expression of ULK1 protein] |
CTD |
PMID:27629431 |
|
NCBI chr12:51,908,105...51,934,704
Ensembl chr12:51,908,448...51,934,702
|
|
G |
Vasp |
vasodilator-stimulated phosphoprotein |
multiple interactions |
ISO |
VASP mutant form promotes the reaction [[TNF co-treated with Cycloheximide] results in increased cleavage of SPTAN1 protein] |
CTD |
PMID:18182247 |
|
NCBI chr 1:80,170,608...80,185,882
Ensembl chr 1:80,170,619...80,185,882
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Lipopolysaccharides results in increased expression of VCAM1 protein] |
CTD |
PMID:12892526 |
|
NCBI chr 2:219,071,193...219,090,931
Ensembl chr 2:219,071,193...219,097,619
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions increases expression |
EXP ISO |
Cycloheximide promotes the reaction [Estradiol results in increased expression of VEGFA mRNA alternative form] Cycloheximide results in increased expression of VEGFA mRNA Cycloheximide inhibits the reaction [sodium arsenite results in increased expression of VEGFA mRNA]; Cycloheximide promotes the reaction [cobaltous chloride results in increased expression of VEGFA mRNA]; Cycloheximide promotes the reaction [nickel chloride results in increased expression of VEGFA mRNA]; Cycloheximide promotes the reaction [Oxygen deficiency results in increased expression of VEGFA mRNA] [Cycloheximide co-treated with Norepinephrine] results in increased expression of VEGFA mRNA |
CTD |
PMID:8344219 PMID:8537383 PMID:10788502 PMID:11641398 |
|
NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
|
|
G |
Vegfd |
vascular endothelial growth factor D |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of VEGFD mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr X:31,816,480...31,852,239
Ensembl chr X:31,816,436...31,851,715
|
|
G |
Virma |
vir like m6A methyltransferase associated |
affects response to substance |
ISO |
VIRMA gene SNP affects the susceptibility to Cycloheximide |
CTD |
PMID:25622337 |
|
NCBI chr 5:25,042,743...25,121,403
Ensembl chr 5:25,042,710...25,120,264
|
|
G |
Vldlr |
very low density lipoprotein receptor |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of VLDLR mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 1:245,236,819...245,273,688
Ensembl chr 1:245,237,736...245,269,205
|
|
G |
Vsnl1 |
visinin-like 1 |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of VSNL1 mRNA] |
CTD |
PMID:11007951 |
|
NCBI chr 6:37,001,360...37,121,969
Ensembl chr 6:37,001,356...37,122,023
|
|
G |
Wwox |
WW domain-containing oxidoreductase |
affects response to substance |
ISO |
WWOX gene SNP affects the susceptibility to Cycloheximide |
CTD |
PMID:25622337 |
|
NCBI chr19:46,761,353...47,695,247
|
|
G |
Xiap |
X-linked inhibitor of apoptosis |
multiple interactions |
ISO |
Cycloheximide inhibits the reaction [Thapsigargin affects the localization of XIAP mRNA] |
CTD |
PMID:29576526 |
|
NCBI chr X:128,409,425...128,455,786
Ensembl chr X:128,409,472...128,453,000
|
|
G |
Yap1 |
Yes1 associated transcriptional regulator |
multiple interactions |
ISO |
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of YAP1 mRNA |
CTD |
PMID:19684285 |
|
NCBI chr 8:6,133,014...6,204,240
Ensembl chr 8:6,135,493...6,203,579
|
|
G |
Yme1l1 |
YME1-like 1 ATPase |
multiple interactions |
ISO |
YME1L1 mutant form inhibits the reaction [Cycloheximide results in increased degradation of TIMM17A protein] |
CTD |
PMID:24315374 |
|
NCBI chr17:89,701,899...89,741,919
Ensembl chr17:89,704,102...89,741,321
|
|